Drug-Conjugate Comprising Quinoline Derivatives
Novel combretastatin-based compounds address the limitations of existing antibody-drug conjugates by providing improved stability, selectivity, and efficacy against resistant tumor cells, enhancing cancer treatment.
Patent Information
- Application Number
- KR1020257007526
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-17
- Filing Date
- 2019-09-17
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2039-09-17
AI Technical Summary
Existing antibody-drug conjugates face limitations such as limited efficacy, selectivity, stability, and susceptibility to multidrug resistance, with combretastatin derivatives not effectively functioning as payloads due to cytotoxicity issues and conjugation difficulties.
Development of novel combretastatin-based compounds with improved chemical stability and selectivity, formulated as antibody-drug conjugates, which are unaffected by multidrug resistance and exhibit high cytotoxicity against resistant tumor cells.
The novel compounds demonstrate enhanced efficacy against cancer cells, particularly resistant tumor cells, with improved chemical stability and specificity, overcoming the limitations of existing payloads.
Smart Images

Figure 112025025529093-PAT00114_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to novel natural product-derived combretastatin-based compounds useful as payloads (also called toxins), particularly in drug conjugates. Additionally, the present invention relates to novel compositions of combretaquinoline comprising those that can be used as payloads, payload-linkers, and drug conjugates, and methods of using these payloads, payload-linkers, and drug conjugates to treat pathologies such as cancer, inflammatory or infectious diseases, for example. Background Technology
[0002] For many types of cancer, conventional chemotherapy remains the only effective form of treatment. Chemotherapy essentially operates based on cytotoxic effects: toxins kill cancer cells to halt tumor growth. Chemotherapy agents primarily damage and destroy cells through high levels of cell division activity. However, these therapies must be improved to better target and destroy malignant cells while minimizing unintended collateral toxicity to normal tissues. In fact, patients still suffer serious adverse effects or side effects because these drugs damage healthy cells as well. Many highly cytotoxic drugs have limited clinical utility because they are equally aggressive toward normal cells as they are toward malignant tumor cells. Healthy tissues can be significantly affected by cytotoxic agents. Since these drugs do not explicitly distinguish between normal and tumor cells, leading to side effects, they are often administered at minimal levels, which tends to reduce their efficacy. This is why finding methods to specifically target tumor cells is crucial.
[0003] Improving the delivery of drugs and other reagents to target cells, tissues, and tumors to achieve maximum efficacy and minimal toxicity has been a significant focus of research over the years. Modern anticancer therapies now use large molecules, such as antibodies, to target cancer more accurately. Antibodies are an important part of the immune system and are large molecules capable of specifically binding to the cell surface of "invaders" (e.g., viruses) to eliminate them. However, antibodies that are often non-healing need to be combined with chemotherapy agents.
[0004] In vivo ( in vivo ) and in vitro ( in vitro In both cases, numerous attempts have been made to develop effective methods for introducing biologically active molecules into cells, but none have proven to be completely satisfactory. Optimizing the association of a drug with its intracellular target while simultaneously minimizing, for example, the intercellular redistribution of the drug to neighboring cells is often difficult, inefficient, or ineffective.
[0005] The concept of antibody conjugates and drugs (also known as "antibody-drug conjugates," or ADCs) aims to overcome these limitations. They consist of three key elements: an antibody (designed to selectively target a tumor of interest), a toxic payload (a cytotoxic compound that kills the tumor, referred to as a "payload" in the field), and a linker (used to conjugate the toxic payload to the antibody). The main advantage of these constructs is that the therapeutic window is significantly enhanced: the half-life and specificity of the toxic payload are increased, and off-target toxicity and efficacy are reduced. The use of ADCs has been the subject of extensive in-depth research over the past 30 years (Moolten et al. (1972), J Natl Cancer Inst. 49 (4): 1057-62; Chari et al, (2014) Angewandte Chemie Int. Ed. 53: 3796-3827; Jackson, (2016) Org. Process Res. Dev. 2016, 20: 852-866). Many ADCs have already been approved and marketed (Roche's Kadcyla and Seattle Genetics' Adcetris).
[0006] The payloads (or toxins) used in ADCs include bacterial toxins such as diphtheria toxin (Levy et al. (1975) Cancer Res. 35(5):1 182-6), plant toxins such as ricin, small molecule toxins such as maytansinoids (EP 1391213; Liu et al., (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623), calicheamicin (Lode et al. (1998) Cancer Res. 58:2925-2928; Upeslacis et al., (1993) Cancer Res. 53, 3336-3342), and auristatins (Sanderson et al. (2005) Clin. Cancer Res. 11:843-52), SN-38 or irinotecan analogs (Govidan et al. (2013) Mol. Cancer. Ther. 12:968-78, US 2014 / 0227180A1, Goldenberg et al. (2007), Clin. Cancer Res. 13, 5556s-5563s), pyrrobenzodiazepines (US 2011 / 0256157A1, Kung Sutherland et al. Blood (2013) 122:1455-1463, Chari et al.,(2009) Mol. Cancer Ther. 8, B126.) or cryptophycines (WO 2011 / 001052A1, Verma et al. (2015) Bioorg. Med. Chem. Lett. Includes 25:864-8, US 2012 / 0225089). Currently, more than 60% of all ADCs currently undergoing clinical evaluation contain toxins associated with monomethylauristatin E and F (tubulin inhibitors MMAE, MMAF). MMAE may be considered by those skilled in the art as a reference standard payload for comparison.
[0007] The conjugation of a drug to an antibody, either directly or via a linker, involves considering various factors including the identification and location of chemical groups for drug conjugation, the mechanism of drug release, structural elements provided for drug release, and structural modifications for the released free drug. Furthermore, if the drug is released after antibody internalization, the mechanism of drug release must correspond to the intracellular trafficking of the conjugate. Therefore, although a certain number of different drug classes have been attempted as payloads, only a few have proven effective as antibody-drug conjugates due to limited efficacy, selectivity, and / or stability (Tolcher et al. (2000) J Clin. Oncol. 18:4000, Laguzza et al (1989) J. Med. Chem. 32:548-555, Uadia P, (1984). Cancer Res. 44:4263-4266). To be effectively qualified as a conjugate, a compound must exhibit cytotoxicity levels lower than the nanomolar IC50 level (Casi and Neri, (2012) J. Control Release. 20;161(2):422-8; Wu and Senter (2005) Nat. Biotechnol. 23(9):137-46). An ideal payload must be free from multi-drug resistance mechanisms (MDR). In the case of MMAEs affected by MDR, some tumors may develop resistance mechanisms (Chen et al., 2015). The few accessible payloads are not effective for a wide range of cancer indications. Due to these limitations, there is a clinical need for novel payloads that are not affected by MDR, possessing a differentiated mode of action, improved selectivity, and toxicity profile. For this reason, combretastatin has been considered a potentially toxic payload.
[0008] In fact, Combretastatin was native to African trees in the 1980s Combretum caffrum It was isolated from the back and was confirmed to have tubulin polymerization inhibitory activity (Pettit GR (1987), J Nat Prod 50: 1 19-131). Combretastatin A-4 (or CA-4) and analogs are cytotoxic and selectively disrupt tumor angiogenesis or prevent neovascularization (Dark et al. (1997) Cancer Res 57, 1829-1834, Grosios K, et al (1999) Br J Cancer 81: 1318-1327). This structurally very simple stilbene CA-4 has several drawbacks, such as low water solubility and chemical instability of the Z-arranged double bond, which is isomerized during storage, administration, and metabolism. Another drawback of CA-4 is that its cytotoxicity is insufficient. This problem was overcome by the development of new derivatives using nitrogen-containing heterocycles, such as quinazoline (see Fig. 1b) and quinoline (see Figs. 1c & d) (Soussi MA et al (2015) Chem. Med Chem. 10(8): 1392-402; I. Khelifi, et al, (2017), European Journal of Medicinal Chemistry 127:1025-1034). Through these derivatives, the 3,4,5-trimethoxyphenyl group, which is considered to be responsible for neurotoxic or cardiotoxic effects, was removed. However, these compounds could not be used as payloads.
[0009] Combretastatin has been cited as a potential payload in some patents, but there is no example or supporting data: (EP 1 912 677 B1 "PSMA antibody-drug conjugates"); WO 2014 / 164534("Site-specific antibody-drug conjugation through glycoengineering"); US 8,535,678 B2("Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders"). On the other hand, combretastatin has been evaluated as a potential payload in the context of several studies, but has not been clinically applied to date due to limited efficacy, safety issues, and an adverse metabolic profile acknowledged by the authors themselves (Toki et al (2002) J. Org. Chem. 67, 1866-1872, Bolu et al (2016) Mol. Pharmaceutics, 13, 1482-1490, R. Nani et al (2015) Angew. Chem. Int. Ed. Engl. 9; 54(46): 13635-13638). The only example of using a combretastatin derivative as a payload comes from a patent application (PCT / EP2018 / 058168) describing a new iso-NH2-combretaquinoline (iso-amino-combretaquinoline). However, the generated ADC Trastuzumab-VC-PAB-ICQO-1 exhibited an IC50 value of 27 µg / mL against the SKBR3 cell line. This cytotoxicity level is 3 log lower than the ng / mL expected from an ADC and is insufficient for therapeutic use. In other words, while these derivatives showed promising characteristics as autonomous derivatives, they appear to lose cytotoxicity upon conjugation. Furthermore, the process of conjugating these derivatives proved difficult and could be a subject for innovative improvement.
[0010] In conclusion, even with the use of new iso-combrettaquinoline derivatives, most conjugation attempts have failed so far. The problem to be solved
[0011] The present invention, therefore, aims to solve one or more of the above-mentioned technical problems.
[0012] In particular, the object of the present invention is to provide a compound useful as a payload (toxic payload or toxin) exhibiting toxicity, stability, and metabolic profile, which is particularly qualified as a payload usable in drug-conjugates.
[0013] The object of the present invention is to provide a novel payload having a differentiated mode of operation, improved selectivity and toxicity profile, and unaffected by multidrug resistance phenomena.
[0014] After a long period of research, surprisingly, the inventors discovered a new compound having a structure that enables its use in antibody-drug conjugates. means of solving the problem
[0015] Accordingly, according to the first aspect, the present invention relates to a compound having the following chemical formula (I):
[0016] (I)
[0017] Here:
[0018] - R1 is -NH2, -NHCOR a , -NHCOOR b , -(C2-C6)alkenylene-CO-NH-OH, -(C2-C6)alkenylene-CO-NH-OH or representing an -OH group;
[0019] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0020] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Indicating energy;
[0021] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Indicating energy;
[0022] - R a represents a -(C1-C5)alkyl or -CF3 group;
[0023] - R b represents a -(C1-C5)alkyl or -CF3 group;
[0024] - R c represents a -(C1-C5)alkyl or -CF3 group; and
[0025] - R d represents a -(C1-C5)alkyl or -CF3 group, and
[0026] In the following state: a base or acid, or a salt of an acid or a salt of a base; or in the form of a hydrate or solvate.
[0027] The inventors have discovered that these compounds exhibit improved efficacy against cancer, particularly against resistant tumor cells. Furthermore, they possess a high level of chemical stability and are unaffected by any isomerization, so they do not tend to become inactive.
[0028] According to a second aspect, the present invention relates to a compound having the following chemical formula (II):
[0029] (II)
[0030] Here:
[0031] - Y1 is -O-, -NH-, -NHCO-, -NHCOR a -, -NHCOO-, -NHCOOR b -, -(C2-C6)alkenylene-CO-NH-O- or -(C2-C6)alkenylene-CO-NH-O-;
[0032] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0033] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Representing a gas; and preferably representing a hydrogen atom;
[0034] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas; and preferably representing a hydrogen atom;
[0035] - R a represents a -(C1-C5)alkylene- or -CF2- group;
[0036] - R b represents a -(C1-C5)alkylene- or -CF2- group;
[0037] - R c represents a -(C1-C5)alkyl or -CF3 group;
[0038] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0039] - L represents the linker;
[0040] - RM * is selected from RM and RM', wherein RM is a reactive functional group capable of forming a covalent bond with a targeting agent moiety, in particular an antibody moiety or a functional fragment thereof, and RM' is an RM moiety having at least one protecting group;
[0041] In the following state: a base or a salt of a base; or in the form of a hydrate or solvate.
[0042] According to a third aspect, the present invention relates to an antibody-drug conjugate having the following chemical formula (III):
[0043] (III)
[0044] Here:
[0045] - Y1 is -O-, -NH-, -NHCO-, -NHCOR a-, -NHCOO-, -NHCOOR b -, -(C2-C6)alkenylene-CO-NH-O- or -(C2-C6)alkenylene-CO-NH-O-;
[0046] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0047] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Representing a gas; and preferably representing a hydrogen atom;
[0048] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas; and preferably representing a hydrogen atom;
[0049] - R a represents a -(C1-C5)alkylene- or -CF2- group;
[0050] - R b represents a -(C1-C5)alkylene- or -CF2- group;
[0051] - R c represents a -(C1-C5)alkyl or -CF3 group;
[0052] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0053] - L' represents the linker;
[0054] - AC represents a targeting agent moiety, particularly an antibody moiety or its functional fragment; and
[0055] Here, the DAR (drug-to-antibody [i.e., targeting agent] ratio) varies between 1 and 8, preferably between 2 and 4.
[0056] As exemplified in the experimental section, and in an unexpected manner, the inventors have shown that these compounds are highly effective compared to known payloads and possess excellent inhibitory activity against numerous cancer cells.
[0057] In particular, the compound having chemical formula (I) is released from the compound having chemical formula (III) in vivo, preferably at a target site.
[0058] Other features, aspects, and advantages of the present invention will become apparent from reading the following detailed description. Effects of the invention
[0059] Included in this specification. Specific details for implementing the invention
[0060] definition
[0061] In the context of the present invention, the following definitions are used:
[0062] - "C t -C z " represents a carbon chain that can have t to z carbon atoms, where t and z can take values from, for example, 1 to 25; for example, C1-C3 is a carbon chain that can have 1 to 3 carbon atoms.
[0063] - The alkyl group represents a linear or branched monovalent saturated aliphatic group, which may include, for example, 1 to 25 carbon atoms, preferably 1 to 5 carbon atoms. Examples may include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl groups, etc.
[0064] - An alkylene refers to a linear or branched, divalent saturated alkyl group that may contain, for example, 1 to 25 carbon atoms.
[0065] - Alkenylene represents an aliphatic hydrocarbon group comprising one linear or branched carbon-carbon double bond, and other bonds may be single bonds or other double bonds, and may comprise, for example, 1 to 25 carbon atoms, preferably 2 to 6 carbon atoms. Examples may be mentioned as etheneylene (-CH=CH-), 1-propeneylene, 2-propeneylene, 1-buteneylene, 2-buteneylene, 3-buteneylene groups, etc.
[0066] - Alkylene represents an aliphatic hydrocarbon group comprising a linear or branched carbon-carbon triple bond, and other bonds may be single bonds, double bonds, or other triple bonds, and may include, for example, 1 to 25 carbon atoms, preferably 2 to 6 carbon atoms. Examples may be mentioned as ethylene, 1-propynylene, 2-propynylene groups, etc.
[0067] - -CF2- A alkyl group refers to a divalent alkyl group in which a hydrogen atom is replaced by two fluorine atoms.
[0068] - Cycloalkylene refers to a monocyclic or polycyclic divalent non-aromatic ring that may contain 3 to 12 carbon atoms. Examples may include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, etc.
[0069] - Cycloalkenylene refers to a monocyclic or polycyclic divalent non-aromatic ring that may contain 3 to 12 carbon atoms and includes one or more unsaturations. Examples include cyclopentenylene and cyclohexenylene.
[0070] - Heterocycloalkylene means a monocyclic or polycyclic divalent non-aromatic ring that may include 3 to 12 carbon atoms and at least one heteroatom selected from O, N or S.
[0071] - Heterocycloalkenylene means a monocyclic or polycyclic divalent non-aromatic ring, which may include 3 to 12 carbon atoms and at least one heteroatom selected from O, N or S, and includes one or more unsaturations.
[0072] - Arrylene means a wholly or partially aromatic divalent ring that may contain 3 to 20 carbon atoms, for example, phenylene.
[0073] - Heteroarylene means a whole or partial aromatic divalent ring that may include 3 to 20 carbon atoms and at least one heteroatom selected from O, N or S.
[0074] - According to the present invention, the term "substituted" refers to one or more hydrogens, for example, alkyl, alkenyl, alkyneyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, aroyl, heteroaroyl, carboxyl, alkoxy, aryloxy, acyloxy, aroyloxy, heteroaroyloxy, alkoxycarbonyl, halogen, (thio)ester, cyano, phosphoryl, amino, imino, (thio)amido, sulfhydryl, alkylthio, acylthio, sulfonyl, sulfate, sulfonate, sulfamoyl, sulfonamido, nitro, azido, haloalkyl, particularly perfluoroalkyl (e.g., trifluoromethyl), haloalkoxy, alkylsulfanyl, alkylsulfinyl, alkylsulfonyl, alkylsulfonylamino, arylsulfonoamino, phosphate, Phosphonate, phosphinate, alkylcarboxy, alkylcarboxyhydroxy, alkylcarboxamide, oxo, hydroxy, mercapto, amino (e.g., optionally uni-substituted or di-substituted by alkyl, aryl, or heteroaryl), imino, carboxamide, carbamoyl (e.g., optionally uni-substituted or di-substituted by alkyl, aryl, or heteroaryl), amidino, aminosulfonyl, acylamino, aroylamino, (thio)ureido, (aryl thio)ureido, alkyl(thio)ureido, cycloalkyl(thio)ureido, aryloxy, aralkoxy, or -O(CH2) n -OH, -O(CH2) n -NH 2, - O(CH2) n COOH, -(CH2) n COOH, -C(O)O(CH2) n R, -(CH2) nIt is understood to indicate that it is replaced by one or more groups selected from N(H)C(O)OR, or -N(R)S(O)2R (wherein is a number from 1 to 4, and R is independently selected by hydrogen or a group selected from -alkyl, -alkenyl, -alkynyl, -cycloalkyl, -cycloalkenyl, -heterocycloalkyl, -heterocycloalkenyl, -aryl and -heteroaryl, and where appropriate, the group or the groups themselves may be substituted).
[0075] The term "reactive functional group" is understood to refer to a functional group capable of forming covalent bonds with other compounds.
[0076] - Moiety refers to a part of a compound.
[0077] - The term "functional fragment" is understood to refer to a part of a compound containing a reactive functional group that is, if possible, protected.
[0078] - The term "protecting group" is understood to refer to a functional group introduced into a molecule from a chemical functional group to mask all or part of the reactivity. Examples may include imides, amides, carbamates, imines, enamines, sulfonylated derivatives, N-sulfonylated, N-alkylated, or N-silylated derivatives, diols, carbonylated derivatives, acetals, ethers, benzyl ethers, silyl ethers, esters, etc.
[0079] - The term "pharmaceuticalally acceptable" is understood to refer to something that is generally safe, non-toxic, biologically or otherwise desirable, and can be used in the manufacture of pharmaceutical compositions that are acceptable for human and / or veterinary pharmaceutical use.
[0080] - The term "salt of an acid or base (acid or base salt)" is understood to refer to a chlorinated acid or base, and, for example, an acid addition salt may be formed from an inorganic acid such as hydrochloric acid, sulfuric acid, or phosphoric acid, or an organic acid such as acetic acid or benzoic acid. A base salt may be formed from an inorganic base such as aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, and sodium hydroxide, or an organic base such as diethanolamine, ethanolamine, N-methylglucarmin, triethanolamine, or tromethamine.
[0081] - The term "hydrate or solvate" is understood to refer to a form of bonding or combination with one or more water molecules or a solvent.
[0082] Compound having chemical formula (I)
[0083] As described above, the object of the present invention is to a compound having the following chemical formula (I):
[0084] (I)
[0085] Here:
[0086] - R1 is -NH2, - NHCOR a , -NHCOOR b , -(C2-C6)alkenylene-CO-NH-OH, -(C2-C6)alkenylene-CO-NH-OH or representing an -OH group;
[0087] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0088] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Indicating energy;
[0089] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Indicating energy;
[0090] - R arepresents a -(C1-C5)alkyl or -CF3 group;
[0091] - R b represents a -(C1-C5)alkyl or -CF3 group;
[0092] - R c represents a -(C1-C5)alkyl or -CF3 group; and
[0093] - R d represents a -(C1-C5)alkyl or -CF3 group, and
[0094] In the following state: a base or acid, or a salt of an acid or a salt of a base; or in the form of a hydrate or solvate.
[0095] Preferably, R3 represents a hydrogen atom.
[0096] Preferably, R4 represents a hydrogen atom.
[0097] According to one preferred embodiment, a compound having chemical formula (I) actually has chemical formula (Ia):
[0098] (Ia)
[0099] Here:
[0100] - R1 is -NH2, -NHCOR a , -NHCOOR b , -(C2-C6)alkenylene-CO-NH-OH, -(C2-C6)alkenylene-CO-NH-OH or representing an -OH group;
[0101] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0102] - R a represents a -(C1-C5)alkyl or -CF3 group; and
[0103] - R b represents a -(C1-C5)alkyl or -CF3 group;
[0104] In the following state: a base or acid, or a salt of an acid or a salt of a base; or in the form of a hydrate or solvate.
[0105] Preferably, R2 represents an -OCH3, -OCH2CH3, or -OCHF2 group, and preferably represents an -OCH3 group.
[0106] Preferably, R1 is -NH2, -NHCOR a , -NHCOOR b , or -OH group, particularly R1 represents -NH2 or -OH group, and preferably -NH2 group.
[0107] According to a much more preferred embodiment, the compound is selected from the following:
[0108] , ,
[0109] and .
[0110] According to one preferred embodiment, a compound having the chemical formula (I) actually has the chemical formula (Ib):
[0111] (Ib)
[0112] Here:
[0113] - R5 is a hydrogen atom, -COR a , or -COOR b Indicating energy;
[0114] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0115] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Representing a gas, and preferably representing a hydrogen atom;
[0116] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas, and preferably representing a hydrogen atom;
[0117] - R a represents a -(C1-C5)alkyl or -CF3 group;
[0118] - R b represents a -(C1-C5)alkyl or -CF3 group;
[0119] - R c represents a -(C1-C5)alkyl or -CF3 group; and
[0120] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0121] In the following state: a base or acid, or a salt of an acid or a salt of a base; or in the form of a hydrate or solvate.
[0122] Preferably, R1 represents a -(C2-C6)alkenylene-CO-NH-OH or -(C2-C6)alkenylene-CO-NH-OH group, and preferably, R1 represents a -CH=CH-CO-NH-OH, -CH=CH-CH2-CH2-CO-NH-OH or -C≡C-CH2-CH2-CO-NH-OH group.
[0123] According to one preferred embodiment, a compound having the chemical formula (I) actually has the chemical formula (Ic):
[0124] (Ic)
[0125] Here:
[0126] - W represents -CH=CH- or -C≡C-;
[0127] - n is 0, 1, 2, 3 or 4, and preferably n is 0 or 2;
[0128] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0129] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR cRepresenting a gas, and preferably representing a hydrogen atom;
[0130] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas, and preferably representing a hydrogen atom;
[0131] - R c represents a -(C1-C5)alkyl group; and
[0132] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0133] In the following state: a base or acid, or a salt of an acid or a salt of a base; or in the form of a hydrate or solvate.
[0134] According to one more preferred embodiment, the compound is selected from the following:
[0135] , ,
[0136] and .
[0137] A method for preparing a compound having the chemical formula (I).
[0138] The present invention relates to a method for preparing a compound of formula (I) according to the present invention, wherein R1 represents an -NH2 or -OH group, and is characterized by the following:
[0139] - A compound having chemical formula (A) undergoes an amination reaction to form a compound having chemical formula (B):
[0140] (A)
[0141] Here, R2 is as defined in the above chemical formula (I), and R9 represents -NO2 or -O-benzoyl group;
[0142] (B)
[0143] Here, R2 is as defined in the above chemical formula (I), and R9 represents -NO2 or -O-benzoyl group;
[0144] - A compound having chemical formula (C) undergoes a cyanide reaction to form a compound having chemical formula (D):
[0145] (C)
[0146] Here, R3 and R4 are as defined in the above chemical formula (I), and
[0147] (D)
[0148] Here, R3 and R4 are as defined in the above chemical formula (I);
[0149] - A compound having chemical formula (B) comes into contact with a compound having chemical formula (D) to form a compound having chemical formula (E) by an aromatic nucleophilic substitution reaction:
[0150] (E)
[0151] Here, R3, R4, and R2 are as defined in the above chemical formula (I), and R 10 represents a -NO2 or -O-benzoyl group;
[0152] - A compound having chemical formula (E) is methylated and then reduced or deprotected to form a compound having chemical formula (I):
[0153] (I)
[0154] Here, R3, R4, and R2 are as defined in the above chemical formula (I), R1 represents an -NH2 or -OH group, and R a and R b is as defined in the above chemical formula (I).
[0155] The present invention also relates to a method for preparing a compound having the formula (I) according to the present invention, wherein R1 represents an -NH2 group and is characterized by the following:
[0156] - A compound having chemical formula (F) undergoes a nitration reaction to form a compound having chemical formula (G):
[0157] (F)
[0158] Here, R2 is as defined in the above chemical formula (I), and
[0159] (G)
[0160] Here, R2 is as defined in the above chemical formula (I);
[0161] - A compound having the chemical formula (H) undergoes a cyanide reaction to form a compound having the chemical formula (D):
[0162] (H)
[0163] Here, R3 and R4 are as defined in the above chemical formula (I), and
[0164] (D)
[0165] Here, R3 and R4 are as defined in the above chemical formula (I);
[0166] - A compound having chemical formula (G) is brought into contact with a compound having chemical formula (J) to form a compound having chemical formula (K) by a coupling reaction in the presence of palladium:
[0167] (K)
[0168] Here, R3, R4 and R2 are as defined in the above chemical formula (I);
[0169] - A compound having the chemical formula (K) undergoes a methylation reaction, followed by a reduction reaction to form a compound having the chemical formula (L):
[0170] (L)
[0171] Here, R3, R4, and R2 are as defined in the chemical formula (I) described above.
[0172] The present invention also relates to a method for preparing a compound according to the present invention, wherein R1 represents a -C2-C6-alkenylene-CO-NH-OH or -C2-C6-alkenylene-CO-NH-OH group, and is characterized as follows:
[0173] - A compound having chemical formula (M) undergoes a cyanide reaction to form a compound having chemical formula (N):
[0174] (M)
[0175] Here, R3 and R4 are as defined in the chemical formula (I) described above, and
[0176] (N)
[0177] Here, R3 and R4 are as defined in the chemical formula (I) described above;
[0178] - A compound having chemical formula (N) comes into contact with a compound having chemical formula (O), and through an aromatic nucleophilic substitution reaction followed by a methylation reaction, forms a compound having chemical formula (P):
[0179] (O)
[0180] Here, R2 is as defined in the above-described chemical formula (I);
[0181] (P)
[0182] Here, R3, R4 and R2 are as defined in the chemical formula (I) described above;
[0183] - The compound of formula (P) undergoes an organometallic coupling reaction with -C2-C6-alkylene-CO-NH-O-(2-tetrahydropyranyl) or -C2-C6-alkylene-CO-NH-O-(2-tetrahydropyranyl) groups, followed by a deprotection reaction to form a compound having formula (I):
[0184] (I)
[0185] Here, R3, R4, and R2 are as defined in the formula (I) described above, and R1 represents a -C2-C6-alkenylene-CO-NH-OH or -C2-C6-alkenylene-CO-NH-OH group.
[0186] According to one preferred embodiment, the present invention relates to a method for preparing a compound according to the present invention, wherein R1 represents an NH2 or -OH group and is characterized by the following:
[0187] - A compound having chemical formula (B) is brought into contact with a compound having chemical formula (D) to form a compound having chemical formula (E) by an aromatic nucleophilic substitution reaction or by a coupling reaction in the presence of a catalyst, particularly a palladium-based catalyst:
[0188] (B)
[0189] Here, R2 is as defined in the chemical formula (I) described above, and R9 represents -NO2 or -O-benzoyl group;
[0190] (D)
[0191] Here, R3 and R4 are as defined in the chemical formula (I) described above;
[0192] (E)
[0193] Here, R3, R4, and R2 are as defined in the formula (I) described above, and R 10 represents a -NO2 or -O-benzoyl group;
[0194] - A compound having chemical formula (E) is methylated and subsequently reduced or deprotected to form a compound having chemical formula (I):
[0195] (I)
[0196] Here, R3, R4, and R2 are as defined in the formula (I) described above, and R1 represents an -NH2 or -OH group, and Ra and R b is as defined in the chemical formula (I) described above.
[0197] According to one preferred embodiment, the present invention relates to a method for manufacturing a compound (Ic), characterized by the following:
[0198] - A compound having chemical formula (N) comes into contact with a compound having chemical formula (O) and, through an aromatic nucleophilic substitution reaction followed by a methylation reaction, forms a compound having chemical formula (P):
[0199] (N)
[0200] Here, R3 and R4 are as defined in the chemical formula (Ic) described above, and
[0201] (O)
[0202] Here, R2 is as defined in the chemical formula (Ic) described above, and
[0203] (P)
[0204] Here, R3, R4, and R2 are as defined in the chemical formula (Ic) described above;
[0205] - A compound having chemical formula (P) undergoes an organometallic coupling reaction with -(C2-C6)alkynylene-CO-NH-O-(2-tetrahydropyranyl) or -(C2-C6)alkynylene-CO-NH-O-(2-tetrahydropyranyl) groups, followed by a deprotection reaction to form a compound having chemical formula (Ic):
[0206] (Ic)
[0207] Here, , n, R3, R4 and R2 are as defined in the chemical formula (Ic) described above.
[0208] Preferably, coupling caused by aromatic nucleophilic substitution is achieved in an acidic medium, particularly in the presence of hydrochloric acid.
[0209] In particular, these occur in polar aprotic solvents, especially dioxane.
[0210] Advantageously, coupling occurs at a temperature of 120°C to 160°C, particularly 130°C to 150°C, especially in the reflux of the solvent.
[0211] Advantageously, the coupling step is performed for 10 to 14 hours, particularly for 11 to 13 hours, preferably for 12 hours.
[0212] In particular, the coupling reaction is selectively coupled with coupling agents such as N-hydroxysuccinimide (NHS), N-hydroxybenzotriazole (HOBt), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysulfosuccinimide (sulfo NHS), dimethylaminopyridine (DMAP), diisopropylethylamine (DIEA), or N-methylmorpholine (NMM), diisopropylcarbodiimide (DIC), dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), carbonyldiimidazole (CDI), It can be carried out in the presence of a coupling agent such as 2-(1H-benzotriazole-1-yl)-2,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), O-(7-aza=benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), (benzotriazole-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) or propylphosphonic acid anhydride.
[0213] In particular, the alkylation, preferably methylation, step of an amine is a reaction well known to those skilled in the relevant technical field who possess all the knowledge necessary for its execution. For example, they can be produced by reacting an amine with a -(C1-C5)alkyl halide in the presence of a base, particularly a carbonate. The -(C1-C5)alkyl halide may preferably be a -(C1-C5)alkyl iodide, a -(C1-C5)alkyl bromide, or a -(C1-C5)alkyl chloride. More specifically, the alkylation step is carried out in a polar aprotic solvent, more preferably in dimethylformamide. Preferably, the alkylation step is carried out at room temperature.
[0214] Amination, cyanation, reduction or deprotection, and even nitration reactions are reactions well known to those skilled in the relevant technical field who possess all the knowledge necessary to carry them out.
[0215] In particular, the amination step can be carried out at 60°C to 100°C, particularly 70°C to 90°C, particularly in the presence of solid iron and hydrochloric acid.
[0216] The manufacturing method according to the present invention may also optionally include a step of chloride of the formed compound to provide a pharmaceutically acceptable salt, particularly in the presence of a pharmaceutically acceptable acid or base.
[0217] The present invention also relates to an intermediate compound selected from the following:
[0218] , ,
[0219] and .
[0220] The present invention also relates to the use of such intermediate compounds for the preparation of compounds having the aforementioned chemical formula (I).
[0221] Compound having chemical formula (II)
[0222] According to another aspect, the present invention relates to a compound having the following chemical formula (II):
[0223] (II)
[0224] Here:
[0225] - Y1 is -O-, -NH-, -NHCO-, -NHCOR a -, -NHCOO-, -NHCOOR b -, -(C2-C6)alkenylene-CO-NH-O- or -(C2-C6)alkenylene-CO-NH-O-;
[0226] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0227] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Representing a gas; and preferably representing a hydrogen atom;
[0228] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas; and preferably representing a hydrogen atom;
[0229] - R a represents a -(C1-C5)alkylene- or -CF2- group;
[0230] - R b represents a -(C1-C5)alkylene- or -CF2- group;
[0231] - R c represents a -(C1-C5)alkyl or -CF3 group;
[0232] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0233] - L represents the linker;
[0234] - RM *is selected from RM and RM', where RM is a reactive functional group capable of forming a covalent bond with a targeting agent moiety, in particular an antibody moiety or its functional fragment, and where RM' is an RM moiety having one or more protecting groups;
[0235] In the following state: a base or a salt of a base; or in the form of a hydrate or solvate.
[0236] According to the first preferred embodiment, L-RM * Gi is selected from the following:
[0237] ,
[0238] ,
[0239] ,
[0240] ,
[0241] ,
[0242] ,
[0243] ,
[0244] ,
[0245] ,
[0246] and .
[0247] According to another preferred embodiment, the compound is selected from the following:
[0248] ,
[0249] ,
[0250] ,
[0251] ,
[0252] and .
[0253] Linker
[0254] The linker or “linker” according to the present invention is a compound that connects two components, each of which is attached to one end of the linker.
[0255] In the case where the link agent is a covalent bond, direct binding to a targeting agent, such as an antibody of a toxic compound ("payload"), can reduce the payload's ability to interact with the targeted molecule within the cell.
[0256] According to a preferred embodiment, the linker increases the distance between the two components, particularly between the payload and the targeting agent, thereby attenuating the steric interference between them.
[0257] In particular, the linker has a continuous chain containing 1 to 30 atoms in the backbone, and the length of the linker is defined by the lowest number of atoms or bonds between the payload and the targeting agent.
[0258] According to one specific embodiment, the linker is optionally substituted, C1-C 20 -alkylene, C1-C 20 -Heteroalkylene, C2-C 20 -Alkenylene, C2-C 20 -Heteroalkenyllene, C2-C 20 -Alkylene, C2-C 20 - Selected from heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or heteroaralkylene groups. The linker may contain one or more elements such as carboxamide, ester, ether, thioether, disulfide, urea, thiourea, hydrocarbon moiety, or derivatives thereof. The linker may contain one or more of these structural elements. Each of these elements may be present in the linker one or more times, for example, two, three, four, five, or even six times.
[0259] According to one specific embodiment, the linker may include a disulfide bond.
[0260] It should be understood that the linker must be attached to the payload and the targeting agent in a single step or multiple steps, for example, two consecutive steps. To this end, the linker has two groups, particularly at the proximal and distal ends, which can (i) form a covalent bond with a group present in one of the components to be linked, particularly a group that is activated on the payload or the targeting agent, or (ii) be activated to form a covalent bond with a group of the payload.
[0261] Accordingly, according to one preferred embodiment, the chemical group present at the end of the linker, which is generated by the coupling reaction, is selected from esters, ethers, urethanes, peptide bonds, etc.
[0262] According to one specific embodiment, the linker L is a linear chain comprising 1 to 20 atoms, particularly 2 to 18 atoms, more particularly 5 to 16 atoms, and preferably 6 to 15 atoms, independently selected from C, O, N and S.
[0263] According to one specific embodiment, at least 60% of the atoms of the linear chain are carbon atoms. In particular, the atoms of the linear chain are connected by single bonds.
[0264] According to one specific embodiment, the linker L is a group selected from alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, or heteroaralkylene, and comprises 1 to 4 heteroatoms selected from N, O, and S, and the linker is optionally substituted.
[0265] According to one specific embodiment, the linker L comprises at least one of a disulfide (-SS-), an ether (-O-), a thioether (-S-), an amine (-NH-), an ester (-OC(=O)- or -C(=O)-O-), a carboxamide (-NH-C(=O)- or C(=O)-NH-), a urethane (-NH-C(=O)-O- or -OC(=O)-NH-), or a urea moiety (-NH-C(=O)-NH-).
[0266] According to one specific embodiment of the present invention, the linker L comprises m groups selected from alkylene, alkenylene, alkynylene, cycloalkylene, heteroalkylene, heteroalkenylene, heteroalkynylene, heterocycloalkylene, arylene, heteroarylene, aralkylene, and heteroaralkylene, each of which may be substituted, and n groups independently selected from at least one of the following groups: disulfide (-SS-), ether (-O-), thioether (-S-), amine (-NH-), ester (-OC(=O)- or -C(=O)-O-), carboxamide (-NH-C(=O)- or C(=O)-NH-), urethane (-NH-C(=O)-O- or -OC(=O)-NH-) or urea It comprises a moiety (-NH-C(=O)-NH-) where m is n + 1. In particular, m is 2 and n is 1, or m is 3 and n is 2. More specifically, the linker comprises two or three unsubstituted alkylene groups and one or two disulfide, ether, thioether, amine, ester, carboxamide, urethane, or urea moiety connected to the unsubstituted alkylene groups.
[0267] According to one specific embodiment, carbon atoms in the linear chain independently form a portion of a selectively substituted methylene group (-CH2-). In particular, the selective substituents are independently selected from halogens and -(C1-C6)alkyl groups, particularly methyl.
[0268] In particular, linker L means that it is a stable linkage agent, that is, stable in (i) the presence of an enzyme and (ii) an intracellular reducing environment.
[0269] According to one specific embodiment, the stable linker does not contain (i) a cleavable enzyme substructure and / or (ii) a disulfide group. In particular, the linker has a length of up to 12 atoms, particularly 2 to 10, more particularly 4 to 9, and even more particularly 6 to 8 atoms.
[0270] According to one other specific embodiment, the linker means that it is a cleavable linkage, that is, (i) cleavable by chemical cleavage, or (ii) a reducible linkage.
[0271] According to one embodiment, the linker can be cleaved by reduction, that is, cleaved in an intracellular reducing environment. In particular, it may be a linker containing a disulfide group, which may result in intracellular release of the payload conjugated to the targeting agent after being internalized by the intracellular reducing environment ( Shen et al., (1985), J Biol. Chem. 260: 10905-10908 ).
[0272] According to one specific embodiment, the linker comprises a disulfide bond, in particular -CMe2-SS-CMe2-moiety. According to another embodiment, the linker is attached to the thiol group of the targeting agent moiety via a disulfide bond.
[0273] According to another embodiment, the linker may be cleaved by chemical cleavage, in particular hydrolysis or proteolysis. In particular, chemical cleavage is catalyzed by an enzyme, i.e., the linker may be cleaved by an enzyme, and in particular, the linker may be cleaved by an enzyme, in particular a lysosomal peptidase such as cathepsin B, which may result in the intracellular release of the payload conjugated to the targeting agent after internalization ( Dubowchik et al., (2002) Bioconjug Chem. 13:855-69According to one specific embodiment, the cleavable linker comprises a dipeptide selected from phenylalanyl-lysine (Phe-Lys), valyl-lysine (Val-Lys), phenylalanyl-alanine (Phe-Ala), valyl-alanine (Val-Ala), phenylalanyl-citrulline (Phe-Cit), and valine-citrulline (Val-Cit). In particular, the cleavable linker further comprises a p-aminobenzyl (PAB) spacer between the dipeptide and the payload.
[0274] According to one embodiment, the linker includes a hydrazone group. In this particular embodiment, cleavage occurs by hydrolysis in the lysosome.
[0275] According to one embodiment, the linker comprises a self-sacrificial linker, i.e., a cleavable link. In particular, after cleavage, fragmentation occurs in which a portion of the linker remaining attached to the payload after cleavage is removed. In particular, the linker may comprise a -(cleavable link)-X-phenyl-CH2-OC(=O)- group, wherein the carbonyl group is attached to an amino group attached to a phenyl ring in the compound according to the present invention, and the compound according to the present invention containing a free amino group is released.
[0276] According to one preferred embodiment, the linker is selected from the following compounds:
[0277] ,
[0278] ,
[0279] ,
[0280] ,
[0281] ,
[0282] .
[0283] As a linker suitable for the present invention, Jun Lu et al. (" Linker shaving a crucial role in antibody-drug conjugates", Int. J. Mol. Sci. 2016, 17, 561 ), Jessica R. McCombs, and Shawn C. Owen (" Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry", The AAPS Journal, vol. 17, No. 2, March 2015, 339 ), Laurent Ducry and Bernhard Stmmp (" Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies", Bioconjugate Chem. 2010, 21, 5-13 ), and Nareshkumar Jain et al. ( "Current ADS linker chemistry, Pharm. Res. 2015, 32: 3526-3540 A linker disclosed in ) may be mentioned.
[0284] Antibody-drug conjugate
[0285] The present invention also relates to an antibody-drug conjugate comprising the compound defined above.
[0286] According to another aspect, the present invention relates to an antibody-drug conjugate having the following chemical formula (III):
[0287] (III)
[0288] Here:
[0289] - Y1 is -O-, -NH-, -NHCO-, -NHCOR a -, -NHCOO-, -NHCOOR b -, -(C2-C6)alkenylene-CO-NH-O- or -(C2-C6)alkenylene-CO-NH-O-;
[0290] - R2 represents -OCH3, -OCH2CH3, -SCH3, -SCH2CH3, or -OCHF2 groups;
[0291] - R3 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR c Representing a gas; and preferably representing a hydrogen atom;
[0292] - R4 is a hydrogen atom or -CH3, -CN, -F, -Cl, or -OR d Representing a gas; and preferably representing a hydrogen atom;
[0293] - R a represents a -(C1-C5)alkylene- or -CF2- group;
[0294] - R b represents a -(C1-C5)alkylene- or -CF2- group;
[0295] - R c represents a -(C1-C5)alkyl or -CF3 group;
[0296] - R d represents a -(C1-C5)alkyl or -CF3 group;
[0297] - L' represents the linker;
[0298] - AC represents a targeting agent moiety, particularly an antibody moiety or its functional fragment; and
[0299] Here, the DAR (drug-to-antibody [targeting agent] ratio) varies between 1 and 8, preferably between 2 and 4.
[0300] Targeting agent
[0301] The term "targeting agent" is understood to refer to a molecule that has an affinity for a biological target. Targeting agents have the function of delivering cytotoxic compounds to biological targets.
[0302] The term "biological target" is understood to refer to an antigen or group of antigens preferably located on the surface of cancer cells. For example, such antigens may be growth factor receptors, mutated "tumor suppressor" oncogene products or genes, angiogenesis-related molecules, or adhesion molecules.
[0303] In particular, the targeting agent is selected from ligands, proteins, antibodies, e.g., monoclonal antibodies, protein or antibody fragments, peptides, oligonucleotides, or oligosaccharides.
[0304] Preferably, it is an antibody (or immunoglobulin) or an antibody fragment.
[0305] As antibodies suitable for the present invention, immunoglobulins IgA, IgD, IgE, IgG, and IgM may be mentioned in particular.
[0306] The antibody may be a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a chimeric antibody, a humanized antibody, or an optimized antibody, for example, an antibody having modified glycosylation or an antibody having a variant Fc region that exhibits optimized binding affinity with one or more Fc receptors. In particular, it is a monoclonal antibody.
[0307] More specifically, antibodies can be selected from the following:
[0308] - Anti-SSA / Ro (anti-Sjögren's syndrome-associated antigen A or anti-Ro) autoantibody, anti-La / SS-B (anti-Sjögren's syndrome type B) autoantibody, anti-centrogen antibody, anti-neuronal nuclear antibody-type 2, anti-dsDNA (anti-double-stranded DNA), anti-RNP (anti-ribonucleoprotein), anti-Smith, anti-focal isomerase antibody, anti-histone antibody, anti-p62 antibody, and anti-sp100 antibody;
[0309] - Anti-glycoprotein 210 antibody;
[0310] - Anti-transglutaminase antibodies including anti-tTG (anti-tissue transglutaminase) antibodies and anti-eTG (anti-epidermal transglutaminase) antibodies;
[0311] - Anti-ganglioside antibody;
[0312] - Anti-actin antibody;
[0313] - Anti-CCP (anti-cyclic citrullinizing peptide) antibody, liver and kidney microsome type 1 antibody;
[0314] - Anti-thrombin antibody;
[0315] - Anti-neutrophil cytoplasmic antibody (ANCA) including anti-myeloid peroxidase (MPO), anti-protease 3 (PR3), anti-lactoferrin, anti-elastase, bacterial inducible protein (BPI), and anti-cathepsin G;
[0316] - Anti-glomerular basement membrane (alpha-3 chain of type IV collagen), anti-phospholipase A2 receptor (PLA2R);
[0317] - Anti-rheumatoid factor antibody;
[0318] - Anti-smooth muscle antibodies including anti-actin antibodies, anti-troponin antibodies, and anti-tropomyosin antibodies;
[0319] - Anti-mitochondrial antibodies including anti-cardiolipin antibody, anti-sulfite oxidase antibody, anti-sarcosine dehydrogenase antibody, and anti-glycogen phosphorylase antibody;
[0320] - Anti-SRP (Signal Recognition Particle) antibody;
[0321] - Anti-VGCC (voltage-gated calcium channel) antibody;
[0322] - Anti-VGKC antibody (voltage-gated potassium channel);
[0323] - Anti-synthetase antibodies including anti-PL7, -PL12, -JO1, -EJ and -JO antibodies;
[0324] - and anti-terminal complement antibodies including anti-factor H autoantibody, anti-Cl inhibitor, anti-C1q, anti-C3, anti-factor B, anti-C3bBb (C3 convertase from alternative complement pathway), and anti-C4b2a (C3 convertase from classical complement pathway).
[0325] As alloantibodies, human platelet antigen antibodies (HPA) and anti-IgA antibodies may be mentioned.
[0326] 인간 치료 항체로서, Panitumumab, Actoxumab, Adalimumab, Adecatumumab, Alirocumab, Anifrolumab, Atinumab, Atorolimumab, Belimumab, Bertilimumab, Bezlotoxumab, Canalumab, Broda, Briakin, Bimag Carlumumab, Cixutumab, Conatumumab, Daratumumab, Denosumab, Drozitumab, Duligotumab, Dupilumab, Dusigitumab, Efungumab, Eldelumab, Enoticumab, Evolocumab, Exbivirumab, Fasinumab, Fezakinumab, Foralmabumab, Fretumumab, Folabravi Fulranumab, Ganitumab, Gantenerumab, Glembatumumab vedotin, Golimumab, Guselkumab, Icrucumab, Inclacumab, Intetumumab, Ipilimumab, Iratumumab, Lerdelimumab, Lexatumumab, Libivirumab, Lirilumab, Lucatumumab, Mavtelimumab, Mavtelimumab Morolimumab, Namilumab, Narnatumab, Nebacumab, Necitumumab, Nesvacumab, Nivolumab, Ofatumumab, Olaratumab, Orticumab, Oxelumab, Panitumab, Panobacumab, Parsatuzumab, Patrificiumab, Placulumab, Pritumumab, Ramu, Ramub Raxibacumab, regavirumab, rilotumab, robotumab,Antibodies selected from the group including Roledumab, Sarilumab, Secukinumab, Seribantumab, Sevirumab, Sirukumab, Stamulumab, Tabalumab, Teprotumumab, Ticilimumab (=tremelimumab), Tovetumab, Tralokinumab, Tremelimumab, Tuvirumab, Urelumab, Ustekinumab, Vantictumab, Vesencumab, Votumumab, Zalutumumab, Zanolimumab, and Ziralimumab may be mentioned.
[0327] As murine (rat) therapeutic antibodies, Abagovomab, Afelimomab, Anatumomab mafenatox, Blinatumomab, Detumomab, Dorlimomab aritox, Edobacomab, Edrecolomab, Elsilimomab, Enlimomab pegol, Epitumomab cituxetan, Faralimomab, Gavilimomab, Ibritumomab tiuxetan, Imciromab, Inolimomab, Lemalesomab, Maslimomab, Minretumomab, Mitumomab, Moxetumomab pasudotox, Muromonab-CD3, Nacolomab tafenatox, Naptumomab estafenatox, Nerelimomab, Odulimomab, Oregovomab, Pemtumomab, Racotumomab, Solitomab, Taplitumomab paptox, Telimomab aritox, tenatumomab, tositumomab, Antibodies selected from the group including Vepalimomab and Zolimomab aritox may be mentioned.
[0328] As chimeric therapeutic antibodies, antibodies selected from the group including Abciximab, Amatuximab, Basiliximab, Bavituximab, Brentuximab vedotin, Cetuximab, Clenoliximab, Ecromeximab, Ensituximab, Futuximab, Galiximab, Girentuximab, Gomiliximab, Indatuximab ravtansine, Infliximab, Keliximab, Lumiliximab, Pagibaximab, Priliximab, Pritoxaximab, Rituximab, Setoxaximab, Siltuximab, Teneliximab, Ublituximab, Vapaliximab, Volociximab, and Zatuximab may be mentioned.
[0329] 인간화된 치료 항체로서, Afutuzumab, Alacizumab pegol, Alemtuzumab, Anrukinzumab, Apolizumab, Aselizumab, Atlizumab(= tocilizumab), Bapineuzumab, Benralizumab, Bevacizumab, Bivacizumab, Mertacizumab Blosozumab, Cantuzumab mertansine, Cantuzumab ravtansine, Caplacizumab, Cedelizumab, Certolizumab pegol, Citatuzumab bogatox, Clazakizumab, Clivatuzumab tetraxetan, Concizumab, Crenezumab, Dacetuzumab, Daclizumab, Dacituzumab, Demlocizumab, Eculizumab, Efalizumab, Elotuzumab, Enavatuzumab, Enokizumab, Epratuzumab, Erlizumab, Etaracizumab, Etrolizumab, Farletuzumab, Felvizumab, Ficlatuzumab, Fontolizumab, Gemtuzumab ozogamicin, Gevokizumab, Ibalizumab, Imagatuzumab, Inogatuzumab ozogamicin, Itolizumab, Ixekizumab, Labetuzumab, Lambrolizumab, Lampalizumab, Lebrikizumab, Ligelizumab, Lintuzumab, Lodelcizumab, Lorvotuzumab mertansine, Margetuximab, Matuzumab, Mepolizumab, Milatuzumab, Motavizumab, Motavizumab Natalizumab, Nimotuzumab, Ocaratuzumab, Ocrelizumab, Olokizumab, Omalizumab, Onartuzumab,Oportuzumab monatox, Ozanezumab, Ozoralizumab, Palivizumab, Pascolizumab, Pateclizumab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab vedotin, Polatuzumab vedotin, Ponezumab, Quilizumab, Ranibizumab, Reslizumab, Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Samalizumab, Sibrotuzumab, Sifalimumab, Simtuzumab, Siplizumab, Solanezumab, Sonepcizumab, Sontuzumab, Suvizumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tanezumab, Tefibazumab, Teplizumab, Tildrakizumab, Tigatuzumab, Antibodies selected from the group including tocilizumab (= atlizumab), toalizumab, trastuzumab, tregalizumab, tucotuzumab celmoleukin, urtoxazumab, vatelizumab, vedolizumab, veltuzumab, visilizumab, and vorsetuzumab mafodotin may be mentioned.
[0330] Preferably, it is a humanized therapeutic antibody, and more preferably, it is Trastuzumab.
[0331] DAR
[0332] The conjugate generally comprises an average number of 1 to 8, preferably 2 to 4, cytotoxic compounds (payloads) linked to a targeting agent (this is the degree of grafting or the "drug-to-antibody [i.e., targeting agent] ratio" (or "DAR")).
[0333] This number can vary significantly depending on the characteristics of the targeting agent, the payload, or the conditions used during bonding.
[0334] If the targeting agent is an antibody, DAR can be determined, for example, by ultraviolet (UV) spectroscopy or by deconvolution of the high-resolution mass spectrometry HRMS spectrum of the conjugate.
[0335] DAR evaluated by UV spectroscopy is Antony S. Dimitrov ( (ed), LLC, 2009, “Therapeutic Antibodies and Protocols”, vol. 525, 445, Springer Science As presented in ). It is referred to as DAR(UV). This method consists of measuring the absorbance of the conjugate solution after the separation step at two wavelengths, WL1 and WL2. The molar extinction coefficients obtained from the naked antibody and the payload prior to conjugation are used. WL1 and WL2, (A WL1 ) and (A WL2 The absorbance of the conjugate solution is measured at the corresponding UV peak of the size exclusion chromatography (SEC) spectrum or using a standard UV spectrophotometer. The absorbance can be expressed in the following format:
[0336] A WL1 = (c D xe D WL1 ) + (c A xe A WL1 )
[0337] A WL2 = (c D xe D WL2 ) + (c A xe A WL2 )
[0338] Here:
[0339] * c D and c A represents the concentration in solution of the portion of the conjugate related to the payload and the portion of the conjugate related to the antibody, respectively;
[0340] * e D WL1 and e D WL2represents the molar extinction coefficient of the payload before junction at wavelengths WL1 and WL2, respectively;
[0341] * e A WL1 and e A WL2 represents the molar extinction coefficients of the naked antibody at wavelengths WL1 and WL2, respectively.
[0342] The term "naked antibody" is understood to mean an antibody without a payload attached, that is, a pre-conjugation antibody.
[0343] Solving these two equations yields the following:
[0344] c D = [(e A WL1 x A WL2 ) - (e A WL2 x A WL1 )] / [(e D WL2 xe A WL1 ) - (e A WL2 xe D WL1) ]
[0345] c A = [A WL1 - (c D xe D WL1 )] / e A WL1
[0346] Then DAR(UV) is c D / c A It corresponds to.
[0347] Alternatively, DAR can be calculated by the deconvolution of the HRMS spectrum of the conjugate and is referred to as DAR(HRMS).
[0348] Manufacturing and bonding methods
[0349] The present invention also relates to a compound having the chemical formula (I) as defined above, the chemical formula XL"-RM * A method for preparing a compound having the formula (II) as defined above, characterized by including a reaction step of reacting with a compound having , wherein:
[0350] - X represents a group capable of reacting with the R1 group defined above;
[0351] - L" indicates a linker;
[0352] - RM * is selected from RM and RM', where RM is a reactive functional group capable of forming a covalent bond with a targeting agent moiety, in particular an antibody moiety or its functional fragment, and where RM' is an RM moiety having one or more protecting groups;
[0353] R1 moiety of the compound having chemical formula (I) and chemical formula XL"-RM * The reaction between compounds containing -Y1-L- RM * It causes the formation of moiety.
[0354] RM * According to one preferred embodiment of this RM, the method further includes a deprotection step of deprotecting an RM' moiety that generates an RM group.
[0355] Preferably, the method comprises a reaction step of reacting a compound having the chemical formula (II) as defined above with a targeting agent moiety.
[0356] Conjugation to the targeting agent moiety can be achieved by coupling a compound structure having the formula (I)-L-RM to a free amino group present in the targeting agent moiety. According to this embodiment, the RM group may be selected from an activated carboxylic acid derivative such as N-hydroxysuccimide ester or an activated carbonate derivative such as isothiocyanate.
[0357] Conjugation to the targeting agent moiety can also be achieved by coupling a compound structure having the formula (I)-L-RM to a free thiol group present in the targeting agent moiety. According to this embodiment, the RM group may be selected from a maleimide group substituted at position 3 or disubstituted at positions 3 and 4 by a leaving group selected from a haloacetyl group, an RM group comprising a receptor-substituted alkene (Michael system), in particular a maleimide group or a propenoil group (Badescu et al., 2014, Bioconjugate Chem., 25: 460-469), a leaving group X, in particular Cl, Br and aryl-S-, in particular phenyl-S-.
[0358] According to one specific embodiment, the thiol group is part of a single uncoupled cysteine residue present in the wild-type targeting agent moiety. According to one other specific embodiment, the thiol group is part of a single uncoupled cysteine residue generated from the wild-type targeting agent moiety, particularly by recombinant genetic engineering, e.g., by insertion into a wild-type sequence, by the removal of a second cysteine forming a disulfide bridge with a first cysteine residue in the wild-type targeting agent moiety, or by the replacement of a non-cysteine residue. According to one other embodiment, the thiol group is generated by the reduction of a disulfide bond between two cystes present in the wild-type targeting agent moiety.
[0359] Conjugation to the targeting agent moiety can also be achieved by coupling a compound structure having the formula (I)-L-RM to two free thiol groups present in the targeting agent moiety. According to this embodiment, the RM group can be selected from maleimide groups disubstituted at positions 3 and 4 with the leaving group X, particularly Cl, Br, and aryl-S-, particularly phenyl-S-.
[0360] According to one embodiment, two thiol groups each form part of a single uncoupled cysteine residue present in the wild-type targeting agent moiety. According to one other specific embodiment, the thiol groups form part of two single uncoupled cysteine residues generated from the wild-type targeting agent moiety, particularly by recombinant genetic engineering, for example by removal by insertion into the wild-type sequence, by the removal of a second cysteine that forms a disulfide bridge with a first cysteine residue in the wild-type targeting agent moiety, or by the replacement of a non-cysteine residue. According to one other embodiment, the two thiol groups are generated by the reduction of the disulfide bond between the two cystes present in the wild-type targeting agent moiety. By the reaction of these two thiol groups with a disubstituted maleimide, the thiol groups are cross-linked, thereby mimicking the originally present disulfide bridge.
[0361] According to one specific embodiment, free thiol groups may be generated by the thiolization of free amino groups present in the targeting agent moiety, in particular by the reaction of these free amino groups with a thiolizing agent selected from derivatives of acylthioacetate (XC(=O)-CH2-SAcyl), such as 2-iminotiolan and N-hydroxysuccinimide ester of acetylthioacetate ( Still et al. , 1984, Can. J. Org. Chem. 62: 586 ).
[0362] Conjugation to the targeting agent moiety can be achieved through coupling to non-natural amino acids introduced by genetic engineering, for example, through the introduction of p-acetylphenylalanine and subsequent oxime ligation ( Kazane et al, (2012) Proc. Natl. Acad. Sci US A, 109: 3731-3736 ).
[0363] Conjugation to the targeting agent moiety can be achieved through the coupling of cyclic diazodicarboxamide to the phenyl ring of a tyrosine residue in the targeting agent moiety ( Ban et al, (2010) J Am. Chem. Soc. 13:1523-5 ).
[0364] Conjugation to the targeting agent moiety can be achieved through 1,3-dipole cycloaddition ("click chemistry").
[0365] According to one embodiment, the targeting agent moiety comprises a double or triple bond, and the compound structure having the formula (I)-L-RM comprises a 1,3-dipole, particularly an azide group. In particular, the targeting agent moiety first reacts with a dibenzocyclooctine-N-hydroxysuccinimide ester or an azadibenzocyclooctine-N-hydroxysuccinimide ester ( Zhou et al, (2013) J Am Chem Soc. 135:12994-7 ).
[0366] According to one other embodiment, the targeting agent moiety comprises a 1,3-dipole, particularly an azide group, and the compound structure having the formula (I)-L-RM comprises a double or triple bond. In particular, the targeting agent moiety is a glycosylated antibody that first reacts with a molecule containing azide by an enzyme-catalyzed reaction ( SiteClick; Zeglis et al, (2013) Bioconjug Chem. 24:1057-67 ). According to one other embodiment, the azido group is incorporated via the non-natural amino acid p-azido-phenylalamine ( Kazane et al, (2012) Proc. Natl. Acad. Sci. USA, 109: 3731-3736 ).
[0367] Pharmaceutical uses
[0368] The present invention also relates to a pharmaceutical composition comprising the antibody-drug conjugate defined above together with a pharmaceutically acceptable carrier.
[0369] In particular, the pharmaceutical composition according to the present invention may include one or more pharmaceutically acceptable excipients.
[0370] The pharmaceutical composition may include one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, lubricants, disintegrants, absorbents, and / or preservatives.
[0371] The present invention also relates to a pharmaceutical composition according to the present invention for use as a medicine, particularly intended for treating cancer.
[0372] The present invention also relates to an antibody-drug conjugate as defined above or a pharmaceutical composition as defined above for use as a pharmaceutical drug.
[0373] The present invention also relates to the antibody-drug conjugate defined above or the pharmaceutical composition as defined above for use in killing or inhibiting cell growth.
[0374] The present invention also relates to an antibody-drug conjugate as defined above or a pharmaceutical composition as defined above for use in cancer treatment.
[0375] Among cancers, various types of leukemia, for example, chronic myeloid leukemia, lymphoma, sarcoma, melanoma, liver cancer, pancreatic cancer, lung cancer, stomach cancer, esophageal cancer, kidney cancer, pleural cancer, thyroid cancer, skin cancer, cervical cancer, breast cancer, ovarian cancer, colorectal cancer, testicular cancer, prostate cancer, bladder cancer, brain cancer, rectal cancer, or bone cancer may be mentioned without limitation.
[0376] In particular, colorectal cancer, lung cancer, especially non-small cell lung cancer, stomach cancer, pancreatic cancer, chronic myeloid leukemia, breast cancer and ovarian cancer, especially breast cancer, may be mentioned.
[0377] Patients who particularly need treatment are mammals, especially humans.
[0378] The present invention also describes a treatment method for cancer treatment comprising administering an effective amount of at least one antibody-drug conjugate according to the present invention to a patient who particularly requires it.
[0379] According to one specific embodiment, the pharmaceutical composition according to the present invention is used in the form of a drug administered systemically.
[0380] Accordingly, the pharmaceutical composition according to the present invention may be intended for administration via a parenteral route. The term parenteral is intended to include injectables and infusions.
[0381] Injectables can be formulated in the form of ampoules or ready-to-use injectable forms, for example, in the form of ready-to-use syringes or single-use syringes, or in practice, in perforable vials for multiple retrievals. Administration of injectables can be performed in the form of subcutaneous (sc), intramuscular (im), intravenous (iv), or intradermal (ic) application. In particular, it is possible to produce suitable injectable formulations in the form of crystals, solutions, nanoparticles, or suspensions of colloidal dispersion systems, such as, for example, hydrosols.
[0382] The injectable composition may be produced in the form of a concentrate that can be further dissolved or dispersed in an isotonic aqueous diluent. The infusion agent may also be prepared in the form of an isotonic solution, a lipid emulsion, a liposomal formulation, and a microemulsion. Similar to the injectable, the infusion agent may also be prepared in the form of a concentrate for dilution. The injectable formulation may also be administered as a permanent infusion in the context of hospital inpatients and outpatient care, for example, using a mini-pump.
[0383] Parenteral drug compositions, e.g., albumin, plasma, diluents, surfactants, organic diluents, pH-influencing substances, composite materials, or polymeric materials, particularly proteins or polymers, may be added as substances that affect the adsorption of the conjugate according to the present invention, or they may also be added for the purpose of reducing the adsorption of the conjugate of the present invention onto an infusion device or packaging material, e.g., a material such as plastic or glass.
[0384] Compounds according to the present invention containing a targeting agent moiety may be bound to microcarriers or parenteral nanoparticles, for example, finely dispersed particles based on poly(meth)acrylates, polylactates, polyglycolates, polyamino acids, or polyether urethanes. Parenteral compositions may also be modified into depot formulations, for example, based on the "multi-unit principle," where the conjugate of the present invention is introduced in a finely dispersed form, a suspension form, or a suspension of crystals in a pharmaceutical product, or based on the "single-unit principle," where the conjugate of the present invention is contained in a formulation, for example, a subsequently implanted tablet or rod. Such implants or drug reservoirs, single-unit and multi-unit formulations, are often composed of so-called biodegradable polymers, for example, polyesters of lactic acid and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates, or polysaccharides.
[0385] The adjuvant and carrier added during the preparation of the pharmaceutical composition according to the present invention, which is formulated as a parenteral product, are particularly sterile water ( Underwater sterilization), substances affecting pH values, e.g., organic or inorganic acids or bases or their salts; buffering substances for adjusting pH values; isotonic substances such as sodium chloride, sodium bicarbonate, glucose, and fructose; surfactants and emulsifiers, e.g., partial esters of fatty acids in polyoxyethylene sorbitan (e.g., Tween®) or fatty acid esters in polyoxyethylene (e.g., Cremophor®); fatty oils, e.g., peanut oil, soybean oil, or castor oil; synthetic esters of fatty acids, e.g., ethyl oleate, isopropyl myristate, and neutral oils (e.g., Miglyol®); as well as polymerization aids, e.g., gelatin, dextran, polyvinylpyrrolidone; additives that increase the solubility of organic solvents, e.g., propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol, or complex-forming substances, e.g., citrate and urea; preservatives, e.g., hydroxypropyl esters and methyl esters of benzoic acid, benzyl alcohol; antioxidants, e.g., sodium sulfite; and stabilizers For example, it is selected from EDTA.
[0386] According to one preferred embodiment, during the formulation of a pharmaceutical composition according to the present invention, the method comprises adding a thickening agent to prevent curing of the conjugate of the present invention, or a complex-forming agent such as a surfactant and a polymer electrolyte and / or EDTA to ensure the returbidity of the precipitate. It is also possible to obtain complexes of various polymers and active ingredients. Examples of such polymers are polyethylene glycol, polystyrene, carboxymethyl cellulose, Pluronics®, or polyethylene glycol sorbitol fatty acid esters. The conjugate of the present invention may also be incorporated into a liquid formulation in the form of an inclusion compound, for example with cyclodextrin. According to one specific embodiment, a dispersant may be added as an additional aid. For the production of lyophilized products, reagents such as mannanite, dextran, sucrose, human albumin, lactose, polyvinylpyrrolidone (PVP), or various gelatins may be used.
[0387] For parenteral administration, the composition may be in the form of an aqueous suspension or a solution that may contain a suspending agent and / or a wetting agent. The composition is advantageously sterile. It may be in the form of an isotonic solution (particularly with respect to blood).
[0388] The compound according to the present invention can be used in pharmaceutical compositions in a dose ranging from 0.01 mg to 1000 mg per day, and can be administered as a single dose once a day or as multiple doses over a day.
[0389] The daily dose administered is advantageously 5 mg to 500 mg, and more advantageously 10 mg to 200 mg.
[0390] However, it may be necessary to use capacities outside this range, and a person skilled in the art can recognize this.
[0391] According to one specific embodiment of the present invention, the compound for use according to the present invention is administered in combination with other active ingredients, particularly anticancer compounds, regardless of whether they are cytotoxic. Accordingly, the pharmaceutical composition according to the present invention may also include other active ingredients.
[0392] Accordingly, the pharmaceutical composition according to the present invention comprises at least one antibody-drug conjugate as defined above and at least one other active ingredient through a combination product for simultaneous or individual use or for use over a period of time, and can be used particularly for cancer treatment.
[0393] In the entire description, including the claims, the term "comprising one" shall be understood as synonymous with "comprising at least one" unless otherwise specified. Expressions "between ... and ..." and "in the range ... to ..." shall be understood to include boundaries unless otherwise specified.
[0394] In the description and embodiments, temperatures are expressed in degrees Celsius unless otherwise indicated, and pressure is atmospheric pressure unless otherwise indicated.
[0395] The present invention is described in more detail through the non-limiting embodiments presented below.
[0396] Examples
[0397] Example 1: Preparation of 4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile
[0398] 1.1 General Overview
[0399]
[0400] 1.2 Preparation of 4-((4-methoxy-3-nitrophenyl)(methyl)amino)quinoline-2-carbonitrile
[0401] In a sealed tube, a chlorinated heterocyclic compound and an aromatic amine derivative are added sequentially to 2 ml of dioxane.
[0402] Then, a drop of HCl is added to the mixture, and the reaction medium is heated to 140°C for 12 hours while stirring.
[0403] After cooling the mixture, NaOH aq It is neutralized with (5N), and the mixture is extracted with ethyl acetate (3 x 10 mL).
[0404] The combined organic phase is dried on a Na2SO4 phase and concentrated under vacuum. The unrefined reaction mixture is dissolved in a dimethylformamide (DMF) solution (5 mL) containing NaH at 0°C. CH3I is added dropwise to this mixture, and the reaction medium is left at ambient temperature under stirring for 2 hours.
[0405] The unrefined reaction mixture is concentrated and purified by chromatography on a silica column.
[0406] 4-((4-methoxy-3-nitrophenyl)(methyl)amino)quinoline-2-carbonitrile is obtained in solid form with a yield of 56%.
[0407] The measured melting temperature is 219.9-220.5℃.
[0408] Specialization 1 H NMR (300 MHz, CDCl3) δ: 8.11 (d, J = 8.5 Hz, 1H); 7.71(t, J = 8.5 Hz, 1H); 7.61(d, J = 8.5 Hz, 1H); 7.58(d, J = 2.7 Hz, 1H); 7.42(t, J = 8.5 Hz, 1H); 7.34(s, 1H); 7.05(dd, J = 9.1 Hz, J = 2.8 Hz, 1H); 6.98(d, J = 9.1 Hz, 1H); 3.94(s, 3H); 3.52(s, 3H).
[0409] Specialization 13C NMR (75 MHz, CDCl3) δ: 153.9; 150.0; 149.3; 142.1; 139.9; 134.3; 130.9; 130.8; 128.2; 127.4; 124.5; 123.6; 118.4; 117.6; 114.9; 114.5; 56.9; 42.9.
[0410] Specialized HRMS C 18 H 15 N4O3: 335.1144(calculated value); 335.1150(observed value).
[0411] Characterized IR neat V max / cm -1 : 2363, 2340, 1679, 1625, 1603, 1460, 1275.
[0412] 1.3 Preparation of 4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile
[0413] In 25 mL of bicol, the nitro compound is added to an ethanol / water mixture [8 / 2]. The reaction medium is heated to 80°C, and solid iron (10 equivalents) and 3 drops of HCl are added to the reaction medium. The entire mixture is heated to 80°C under stirring until the nitro compound is completely reduced.
[0414] The unrefined reaction mixture is cooled to ambient temperature and filtered through filter paper. The filtrate is concentrated and purified by chromatography on a silica column to obtain the reduction product.
[0415] 4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile is obtained in solid form with a yield of 62%.
[0416] The measured melting temperature is 84.9-92.6℃.
[0417] Specialization 1H NMR (300 MHz, CDCl3) δ: 7.98 (d, J = 8.4 Hz, 1H); 7.59(t, J = 9.2 Hz, 2H); 7.26(d, J = 8.3 Hz, 1H); 6.68(d, J = 8.5 Hz, 1H); 6.46(d, J = 2.5 Hz, 1H); 6.36(dd, J = 8.5 Hz, J = 2.5 Hz, 1H); 3.88(s, 2H); 3.84(s, 3H); 3.42(s, 3H).
[0418] Specialization 13 C NMR (75 MHz, CDCl3) δ: 154.5; 149.7; 144.9; 143.5; 137.5; 134.0; 130.1; 129.9; 126.7; 125.6; 123.0; 118.2; 113.6; 111.0; 110.9; 110.7; 55.7; 43.8.
[0419] Specialized HRMS C 18 H 17 N4O: 305.1402(calculated value); 305.1399(observed value).
[0420] Characterized IR neat V max / cm -1 : 3475, 3377, 2960, 2837, 2236, 1570, 1502, 1264.
[0421] Characterization (Liquid Chromatography / Mass Spectroscopy) LC-MS: tr 15.36.
[0422] Purity: 95.47%.
[0423] Example 2: Preparation of 4-(3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile
[0424] 2.1 Preparation of 4-(3-iodo-4-methoxyphenyl)amino)quinoline-2-carbonitrile
[0425]
[0426] The following are mixed in a sealed tube: 4-chloroquinoline-2-carbonitrile (376 mg, 2.00 mmol, 1 equivalent) and 3-iodo-4-methoxycyaniline (500 mg, 2.00 mmol), dioxane (10 mL), and concentrated HCl (5 drops).
[0427] The mixture is heated at 140°C overnight.
[0428] After the reaction medium is cooled, the mixture is neutralized to a neutral pH and extracted with ethyl acetate. The organic phase is dried on the MgSO4 phase.
[0429] The unrefined residue is purified by chromatography (cyclohexane: ethyl acetate 0 → 30%) on silica gel.
[0430] 4-(3-iodo-4-methoxyphenyl)amino)quinoline-2-carbonitrile is separated in the form of a yellow solid with a yield of 51%.
[0431] Specialization 1 H NMR (300 MHz, CDCl3) δ: 8.11 (d, J = 8.5 Hz, 1H); 7.92(d, J = 7.7 Hz, 1H); 7.86-7.74(m, 2H); 7.71-7.60(m, 1H); 7.33 (dd, J = 8.3; 2.7 Hz, 1H); 7.00-6.88(m, 2H); 6.73(s, 1H); 3.98(s, 3H).
[0432] Characterized Electrospray Ionization-High Resolution Mass Spectrometry (ESI) + ) HRMS: m / z for C 17 H 13 N3OI [M+H] + 402.0103(calculated value); 402.0113(found value).
[0433] 2.2 Preparation of 4-((3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile
[0434]
[0435] NaH (70.0 mg, 2.17 mmol) is added to a solution of 4-((3-iodo-4-methoxyphenyl)amino)quinoline-2-carbonitrile (219 mg, 0.54 mmol) dissolved in dimethylformamide (DMF) (5 mL) at 0°C. CH3I (305 mg, 2.17 mmol) is added dropwise. The mixture is stirred at 0°C for 30 minutes.
[0436] The mixture is brought to ambient temperature, diluted with water, extracted with ethyl acetate, and dried on MgSO4.
[0437] The unrefined residue is purified by chromatography (cyclohexane:ethyl acetate 0 → 40%) on silica gel.
[0438] Compound 4-((3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile is isolated in the form of a yellow solid with a yield of 71%.
[0439] Specialization 1 H NMR (300 MHz, CDCl3) δ: 8.08 (d, J = 8.4 Hz, 1H); 7.79-7.51(m, 3H); 7.48-7.21(m, 2H); 6.92 (dd, J = 8.7; 2.7 Hz, 1H); 6.73(d, J = 8.8 Hz, 1H); 3.88(s, 3H); 3.48(s, 3H).
[0440] Specialization 13 C NMR (75 MHz, CDCl3) δ: 155.49; 154.17; 149.84; 144.02; 134.25; 134.19; 130.56; 130.29; 127.41; 125.07; 124.27; 123.06; 117.91; 112.35; 111.28; 86.64; 56.66; 43.64.
[0441] Characterization (ESI) + ) HRMS: m / z C 18 H 15 N3OI [M+H] + 416.02 260(calculated value); 416.0267(found value).
[0442] Characterized IR(neat): 1571, 1562, 1482, 1430, 1279, 1109, 808, 766, 713, 603 cm -1 .
[0443] Melting point = 175-180℃.
[0444] Example 3: Preparation of (E)-5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-enamide
[0445] 3.1 Preparation of N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-enamide
[0446]
[0447] One equivalent of carboxylic acid is mixed with one equivalent of NHTHP in dichloromethane (DCM). One equivalent of DCC (dicyclohexylcarbodiimide) is then added. The mixture is stirred overnight at ambient temperature and then washed with a saturated bicarbonate solution and water. The residue is purified by chromatography (cyclohexane:ethyl acetate 1:1) on silica gel.
[0448] N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-enamide in the form of a white solid is obtained in a yield of 86%.
[0449] Specialization 1 H NMR (300 MHz, DMSO) δ: 10.93 (s, 1H); 5.78 (dq, J = 10.6; 6.6 Hz, 1H); 5.00 (dd, J = 21.1; 13.7 Hz, 2H); 4.80(s, 1H); 3.92(m, 1H); 3.50(m, 1H); 2.24(m, 2H); 2.08(m, 2H); 1.69-1.51(m, 6H).
[0450] 3.2 Preparation of (E)-5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-enamide
[0451]
[0452] The following is added to a sealed tube purged with argon gas: 4-((3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile prepared in Example 2 above (30.0 mg, 0.072 mmol), N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-enamide (42.0 mg, 0.20 mmol), tri(o-tolyl)phosphine (7.20 mg, 0.023 mmol), Pd(OAC)2 (6.0 mg, 0.026 mmol), EtN3 (49.0 mg, 0.48 mmol), and DMF (1 mL); the mixture is degassed and heated overnight at 100°C.
[0453] The reaction medium is brought to ambient temperature, diluted with DCM, filtered through Celite, and then the filtrate is evaporated. The formation of the intermediate compound (see schematic diagram above) is confirmed by liquid chromatography / mass spectrometry (LC / MS), and the compound is used in subsequent steps without purification.
[0454] A 4N HCl solution in dioxane (0.5 mL) is added to a solution of the intermediate compound (see schematic above) in anhydrous dioxane (1 mL). The mixture is stirred at ambient temperature for 30 minutes, then evaporated at ambient temperature, and subsequently purified by high-performance liquid chromatography (HPLC) using a gradient of acetonitrile in water. After freeze-drying, the compound (E)-5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-enamide is obtained in the form of a yellow solid in a yield of 30%.
[0455] Characterization (ESI) + ) HRMS: m / z C 23 H 23 N4O3[M+H] + : 403.1770(calculated value); 403.1768(found value).
[0456] Characterized IR(neat): 2947, 1641, 1569, 1491, 1235, 1031, 970, 758 cm -1 .
[0457] Purity (HPLC): 100%.
[0458] Specialization 1H NMR (400 MHz, MeOD) δ: 7.89 (d, J = 8.3 Hz, 1H); 7.61(t, J = 7.4 Hz, 1H); 7.53-4.45(m, 1H); 7.34(m, 1H); 7.24-7.23(m, 3H); 6.87(m, 3H); 6.67(d, J = 15.9 Hz, 1H); 6.17-6.04(m, 1H); 3.81(s, 3H); 3.48(s, 4H); 2.46 (dd, J = 13.5; 6.7 Hz, 2H); 2.28-2.16(m, 2H).
[0459] Specialization 13 C NMR (101 MHz, MeOD) δ: 172.04; 156.07; 155.65; 150.60; 144.35; 134.94; 131.31; 131.22; 130.31; 129.22; 127.66; 126.91; 126.25; 125.32; 123.70; 123.63; 118.85; 113.20; 111.66; 56.24; 44.45; 33.52; 30.33.
[0460] Melting point = 177-182℃.
[0461] Example 4: Preparation of 5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-inamide
[0462] 4.1 Preparation of N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-inamide
[0463]
[0464] One equivalent of carboxylic acid is mixed with one equivalent of NHTHP in DCM. One equivalent of (dicyclohexylcarboimide) DCC is subsequently added. The mixture is stirred overnight at ambient temperature and then washed with a saturated bicarbonate solution and water. The residue is purified by chromatography (cyclohexane:ethyl acetate 1:1) on silica gel.
[0465] N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-inamide in the form of a white solid is obtained in a yield of 76%.
[0466] Specialization 1H RMN (300 MHz, DMSO) δ: 11.04 (s, 1H); 4.80(s, 1H); 3.91(s, 1H); 3.50(d, J = 11.6 Hz, 1H); 2.80(s, 1H); 2.35(d, J = 6.2 Hz, 2H); 2.18(t, J = 7.0 Hz, 2H); 1.58(m, 6H).
[0467] 4.2 Preparation of 5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-inamide
[0468]
[0469] The following is added to a sealed tube purged with argon: 4-((3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile prepared in Example 2 above (30.0 mg, 0.072 mmol), N-((tetrahydro-2H-pyran-2-yl)oxy)pent-4-inamide (28.0 mg, 0.144 mmol), PdCl2P(Ph3)2 (12 mg, 0.017 mmol), CuI (7 mg, 0.036 mmol), Et3N (21.0 mg, 0.22 mmol), and DMF (1 mL).
[0470] The mixture is degassed and stirred overnight at ambient temperature. The reaction mixture is diluted with DCM, filtered through Celite, and the filtrate is evaporated. The formation of the intermediate compound (refer to the reaction scheme above) is confirmed by liquid chromatography / mass spectrometry (LC / MS), and the compound is used in subsequent steps without purification.
[0471] A 4N HCl solution in dioxane (0.5 mL) is added to a solution of an intermediate compound (see schematic above) (29.0 mg, 0.06 mmol) in dioxane anhydrous (1 mL). The mixture is stirred at ambient temperature for 30 minutes and then evaporated at ambient temperature, after which it is purified by high-performance liquid chromatography (HPLC) using a gradient of acetonitrile in water.
[0472] After freeze-drying, the compound 5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-inamide is obtained in the form of a yellow solid with a yield of 15%.
[0473] Specialization 1 H NMR (400 MHz, MeOD) δ: 8.54 (s, 1H); 7.93(d, J = 8.3 Hz, 1H); 7.72-7.49(m, 2H); 7.30-7.27(m, 2H); 7.18-6.85(m, 3H); 3.83(s, 3H); 3.47(s, 3H); 2.70(s, 2H); 2.34(s, 2H).
[0474] Specialization 13 C NMR (101 MHz, DMSO) δ: 167.20; 156.84; 153.86; 149.09; 142.69; 133.65; 130.27; 129.92; 128.30; 127.21; 125.14; 125.05; 122.31; 118.06; 113.16; 112.43; 112.11; 94.05; 76.58; 55.84; 43.65; 40.15; 39.94; 39.73; 39.52; 39.31; 39.10; 38.89; 31.49; 15.41.
[0475] Characterization (ESI) + ) HRMS: m / z C 23 H 21 N4O3[M+H] + 403.1614(calculated value); 403.1621(found value).
[0476] Characterized IR(neat): 2987, 1644, 1496, 1066, 766 cm -1 .
[0477] Purity (HPLC): 100%.
[0478] Melting point = 170-175℃.
[0479] Example 5: Preparation of (E)-3-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamide
[0480] 5.1 Preparation of N-((tetrahydro-2H-pyran-2-yl)oxy)acrylamide
[0481]
[0482] One equivalent of carboxylic acid is mixed with one equivalent of NHTHP in DCM. One equivalent of (dicyclohexylcarboimide) DCC is then added. The mixture is stirred overnight at ambient temperature and then washed with a saturated bicarbonate solution and water. The residue is purified by chromatography (cyclohexane:ethyl acetate 1:1) on silica gel.
[0483] N-((tetrahydro-2H-pyran-2-yl)oxy)acrylamide is obtained in the form of a white solid with a yield of 61%.
[0484] Specialization 1 H NMR (200 MHz, CDCL) δ: 9.41 (s, 1H); 6.40(d, J = 16.7 Hz, 1H); 6.15(s, 1H); 5.69(d, J = 10.4 Hz, 1H); 4.97(s, 1H); 3.96(t, J = 8.1 Hz, 1H); 3.59 (dd, J = 11.3; 4.0 Hz, 1H); 1.77(d, J = 10.9 Hz, 3H); 1.58(s, 3H).
[0485] 5.2 Preparation of (E)-3-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamide
[0486]
[0487] The following is added to a sealed tube purged with argon: 4-((3-iodo-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile prepared in Example 2 above (30.0 mg, 0.072 mmol), N-((tetrahydro-2H-pyran-2-yl)oxy)acrylamide (34.0 mg, 0.20 mmol), tri(o-tolyl)phosphine (7.20 mg, 0.023 mmol), Pd(OAC)2 (6.0 mg, 0.026 mmol), EtN3 (49.0 mg, 0.48 mmol), and DMF (1 mL). The mixture is degassed and heated overnight at 100°C.
[0488] The reaction medium is brought to ambient temperature, diluted with DCM, filtered through Celite, and the filtrate is evaporated. The formation of the intermediate compound (see schematic diagram above) is confirmed by liquid chromatography / mass spectrometry (LC / MS), and the compound is used in subsequent steps without purification.
[0489] A 4N HCl solution in dioxane (0.5 mL) is added to a solution of the intermediate compound (see schematic above) in anhydrous dioxane (1 mL). The mixture is stirred at ambient temperature for 30 minutes and then evaporated at ambient temperature, after which it is purified by high-performance liquid chromatography (HPLC) using a gradient of acetonitrile in water.
[0490] After freeze-drying, compound (E)-3-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamide is obtained in the form of a yellow solid with a yield of 55%.
[0491] Specialization 1 ¹H NMR(300 MHz, MeOD) δ: 7.94(d, J = 8.2Hz, 1H); 7.82-7.48(m, 3H); 7.44(s, 1H); 7.29(s, 2H); 7.07(dd, J = 29.0; 8.9Hz, 2H); 6.42(d, J = 17.0Hz, 1H); 4.85(peak corresponding to hydrochloride overlapping with water), 3.90(s, 3H); 3.53(s, 3H).
[0492] Specialization 13 C NMR (75 MHz, MeOD) δ: 165.03; 155.74; 154.66; 149.31; 143.14; 134.58; 133.72; 130.06; 129.10; 126.58; 125.39; 124.73; 123.80; 122.40; 118.50; 117.41; 112.46; 110.98; 55.02; 42.86.
[0493] Characterization (ESI) + ) HRMS: m / z C 21 H 19 N4O3[M+H]+ 375.1457(calculated value); 375.1455(found value).
[0494] Characterized IR(neat): 3213, 1567, 1492, 1427, 1241, 1105, 977, 762 cm -1 .
[0495] Purity (HPLC): 100%.
[0496] Melting point = 215-210℃.
[0497] Example 6: Comparison of the antiproliferative activity of the compound of the present invention (referred to as "ICQN") in free and unconjugated forms against cancer cell lines
[0498] IC of compounds according to the present invention 4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile (ICQN-1); 5-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxypent-4-inamide (ICQN-2); and (E)-3-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamide (ICQN-3) 50 (Depending on the terminology accepted) activity was compared with compounds of the prior art and commercial and clinical reference compounds, in particular MMAE (monomethylauristatin E).
[0499] IC 50 Activity was measured in various cancer cell lines HCT116 (colorectal tumor), A549 (non-small cell lung cancer), NCI-N87 (gastric tumor), Mia-Paca-2 (pancreatic tumor), K562R (chronic myeloid leukemia), SKOV3 (ovarian tumor), SKBr3 (breast tumor, Her2 overexpression), MCF7 (breast tumor) and MDA-MB231 (breast tumor).
[0500] Cancer cell lines were obtained from the American Culture Collection (ATCC, Rockville, MD), the German Collection of Microbial and Cell Culture at the Leibniz Institute (DSMZ, Braunschweig-Germany), or the European Collection of Cell Culture (ECACC, UK). Cancer cell lines were cultured according to the supplier's instructions.
[0501] HCT-116 human colorectal carcinoma, SK-BR3 breast carcinoma, and SK-OV-3 ovarian carcinoma cells were cultured in Gibco McCoy's 5A medium supplemented with 10% fetal bovine serum (FCS) and 1% glutamine.
[0502] A549 lung carcinoma cells, K562R myeloid leukemia cells, and NCI-N87 gastric carcinoma cells were cultured in Gibco Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FCS) and 1% glutamine. Mia-Paca2 carcinoma cells were cultured in Gibco Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FCS) and 1% glutamine.
[0503] Breast adenocarcinoma cells MDA-MB231 and MCF7 were cultured in Gibco RPMI 1640 culture medium supplemented with 10% fetal bovine serum (FCS) and 1% glutamine.
[0504] Cells were counted using Vi-cell XR (Beckman Coulter), and cell viability was evaluated using a 0.25% trypan blue dye exclusion assay. The presence of Mycoplasma in the cells was tested using the Mycoplasma PCR detection kit (Applied Biological Materials Inc., Canada) according to the manufacturer's instructions, and only Mycoplasma-free cells were used in the study. The cell lines were maintained at 37°C in a humidified atmosphere containing 5% CO2.
[0505] IC 50 For the measurement, cells were placed in a 96-well plate (3 x 10⁶) containing 100 μl of growth medium. 3Cells were seeded into wells. After 24 hours of incubation, cells were treated with the tested compounds at 10 different final concentrations. Each concentration was obtained from serial dilutions in the culture medium starting from the stock solution. Control cells were treated with a carrier. The experiment was performed three times.
[0506] Measurements were performed after 72 hours of treatment using a PolarStar Omega microplate reader (BMG-Labtech) and a CellTiter Glo assay (Promega) that enables the measurement of the number of living cells through bioluminescence (quantification of adenosine triphosphate-ATP).
[0507] The dose-response curve was plotted using the Graph Prism software application and IC 50 The values were calculated using Graph Prism software based on a polynomial curve (a 4- or 5-parameter logistic equation).
[0508] The results are shown in Table 1 below.
[0509] As shown by these results, the compound according to the present invention exhibits excellent inhibitory activity against a number of cancer cell lines.
[0510] cell line HCT116 IC 50 (nM) A549 IC 50 (nM) NIC-N87 IC 50 (nM) Mia-Paca-2 IC 50 (nM) K562R IC 50 (nM) SKOV3 IC 50 (nM) SKBr3 IC 50 (nM) MCF7 CI 50 (nM) MDA-MB231 CI 50 (nM) 4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile ICQN-1 0.23 0.72 0.30 0.49 0.47 0.44 0.36 0.17 0.34 MMAE(GOLD STANDARD) 1.52 4.12 6.58 3.02 19.70 0.08 0.06 0.58 1.25 4-((3-amino-4-ethoxyphenyl)(methyl)amino)quinoline-2-carbonitrileICQN-2 / / 0.93 0.29 0.36 0.59 0.38 / / (E)-3-(5-((2-cyanoquinoline-4-yl)(methyl)amino)-2-methoxyphenyl)-N-hydroxyacrylamideICQN-3 / / 0.10 0.94 0.56 2.64 1.78 0.78 0.44
[0511] IC for cell lines HCT116, A549, NCI-N87, Mia-Paca-2, K562R, MCF7, and MDA-MB231 50 The results are overall significantly superior to those obtained with the commercial and clinical reference compound MMAE. It must be reiterated to emphasize that the selection of cell lines is based on a wide range of solid and liquid cancer indications, representing unmet medical needs in the contexts where conjugated antibodies are relevant. This cytotoxicity observed across a broad panel is also a benchmark for commercial success for the payload.
[0512] Example 7: Comparative analysis of the antiproliferative activity of commercial and clinical reference compounds MMAE and the compounds of the present invention (in unconjugated form).
[0513] IC 50 The ratio was established between the compound of the present invention (ICQN-1) and MMAE. IC 50 The higher the ratio, the greater the potential for therapeutic improvement, which increases the likelihood of commercial success.
[0514] cell line HCT116 A549 NCI-N87 Mia-Paca-2 MCF7 MDA-MB231 IC 50 ICQN1 / MMAE ratio 7 6 22 6 3 4
[0515] Therefore, the compound according to the present invention demonstrates a significant advantage over MMAE. For example, in relation to the NCI-N87 (gastric cancer) cell line, ICQN1 is 22 times more effective than MMAE.
[0516] Example 8: Antiproliferative activity compared with a prior art compound having a quinoline nucleus and an aromatic ring interconnected by an N-Me group (L. Chen et al. Eur. J. Med. Chem. 2017, 138 , 1114).
[0517] In the work published by Chen et al. cited above, compound 13b has the following structure:
[0518]
[0519] This compound 13b has an IC50 of 3.2 nM in the MDA-MB-231 cell line. 50 It shows.
[0520] Table 3 below shows the compound according to the present invention (ICQN-1(4-((3-amino-4-methoxyphenyl)(methyl)amino)quinoline-2-carbonitrile)) and compound 13b described by L. Chen et al. ( Eur. J. Med. Chem. 2017, 138, 1114 Provides collective comparative data for 7 cell lines regarding ).
[0521] HCT116 A549 NCI-N87 Mia-Paca2 K562R SKOV3 SKBr3 Prior art compound 13b according to L. Chen et al. 2.15 0.68 4.36 0.92 3.59 1.28 2.17 Compound according to the present invention (compound ICQN1 ) 0.23 0.72 0.30 0.49 0.47 0.44 0.36 Ratio of 13b vs. ICQN-1 activity ~10 1 15 2 8 3 6
[0522] Quite surprisingly, the compound of the present invention possesses a much greater total cytotoxic activity than compound 13b. The resulting activity obtained after substituting the Me group with CN at position 2 of the quinoline is unexpected and could not have been predicted by those skilled in the art. In fact, according to L. Chen et al. and those skilled in the art, the methyl at position 2 of the quinoline was considered necessary to maintain inhibitory activity. Furthermore, according to L. Chen et al., there is no mention of any conjugation or application in the context of an ADC strategy.
[0523] Example 9: Antiproliferative activity compared with a prior art compound having a dihetroarylmethylamine type structure (Alami et al.)
[0524] Alami et al. Eur. J. Med. Chem. 2019, 168, 176-188 Accordingly, by comparing the molecules la and lb (structural formulas below), those skilled in the field noted that replacing Me with CN at position 2 of the quinoline causes a sharp decrease in cytotoxic activity (factor 170 compared to the HCT116 cell line).
[0525]
[0526] However, as supported by Example 8 above, replacing Me with CN at position 2 of the quinoline induces a remarkable improvement in cytotoxicity (by factor 10). A person skilled in the art would not have anticipated, nor could have anticipated, such activity in relation to the compound according to the present invention.
[0527] In addition, it should be noted that compound 1a according to Alami et al. cannot be considered as a payload in the context of an ADC strategy because it lacks an anchor point for binding to a linker.
[0528] Example 10: Antiproliferative activity compared with a prior art compound having a di(heteroaryl)arylethylene type structure
[0529] Alami et al. J. Med. ChemAccording to . 2019, 62, 1902-1916, by comparing molecules 4f / 4j and 4g / 4k having a double bond instead of an N-Me group two at a time, a person skilled in the art can see that replacing Me with CN at the 2nd position of quinoline results in a cytotoxic activity IC₀ of less than 1 nM against cell line HCT116. 50 You will find that it did not provide the ability to anticipate achieving improvement. Those skilled in the art have noted the loss of activity when transferred from compound 4f (Me at position 2) to compound 4j (CN at position 2).
[0530] IC 50 (HCT116) nM 2 12 5.7 3.4
[0531] Example 11: Comparative analysis of the antiproliferative activity of the compound of the present invention compared with the payload of prior art ICQO-1 Among all compounds identified in the prior art, ICQO-1 is the only compound that exhibits payload characteristics according to those skilled in the art. ICQO is a compound disclosed in international patent application PCT / EP2018 / 058168 and has the following structure:
[0532]
[0533] IC 50 The ratio was established between the compound of the present invention (ICQN-1) and the compound of the prior art ICQO-1. A higher ratio indicates greater potential therapeutic activity in vivo.
[0534] cell line HCT-116 SKOV-3 ICQN-1 vs ICQO-1 44 3
[0535] The ratio indicates that the compound of the present invention (ICQN) demonstrates a significant advantage over compounds of the ICQO-1 type. For example, in the context of the HCT-116 (colorectal cancer) cell line, ICQN-1 is 44 times more effective than the payload compound ICQO-1. This significant difference was unpredictable and unexpected, particularly to those skilled in the relevant technical field.
[0536] Example 12: Comparative analysis of the antiproliferative activity of ICQN compared with a quinoline-type prior art compound (Patent application US 2006 / 074187, Example 21)
[0537] VB118 is a quinoline compound that was synthesized and described in comparison to the compound according to the present invention (Patent Application US 2006 / 074187, Example 21).
[0538] cell line ICQN2 ICQN1 VB118 NCI-N87 0.93 0.30 >100 nM Mia-Paca-2 0.29 0.49 >100 nM K562R 0.36 0.47 >100 nM SKOV-3 0.59 0.44 >100 nM SKBR3 0.38 0.36 >100 nM
[0539] The addition of a nitrile functional group and an amine functional group -NH2 at position 2 of the quinoline on the compound (ICQN) according to the present invention induces a remarkable increase in activity of at least 2 log compared to the VB118 type of prior art compound for a wide range of cell lines and cancer indications.
[0540] Example 13: Comparative analysis of the antiproliferative activity of the compound of the present invention (ICQN) compared with commercial reference compound MMAE and payload ICQO-1 against resistant cancer cells (MDR profile: multidrug resistance)
[0541] K562R (chronic myeloid leukemia) cells have an MDR profile that can be resistant to several chemotherapy compounds, including the reference compound MMAE.
[0542] K562R(PgP+) Ratio vs MMAE Ratio vs ICQO-1 MMAE 35 nM ICQO-1 1.98 nM 17 ICQN-1 0.47 nM 74 4.2
[0543] Within the field of payloads and conjugated pharmaceuticals, those skilled in the relevant technical field are IC 50 It should be noted that a payload such as MMAE at 35 nM provides lower therapeutic interest than the compound according to the present invention. Once conjugated, the payload preferably possesses sub-nanomolar activity against the targeted cancer line to exert efficacy. The compound ICQN-1 according to the present invention was found to exhibit superiority that is 74 times greater than MMAE and 4.2 times greater than that of the compound ICQO-1. The compound according to the present invention exhibits particularly remarkable activity and also demonstrates therapeutic differentiation against cancers with a multi-drug resistance (MDR) profile.
[0544] Example 14: Preparation of Conjugated Antibody
[0545] Various other "toxin-linker" compounds (valine-citrulline type), cleavable (by cathepsin B enzyme), and non-cleavable enzymes were obtained as disclosed in Table 8 below:
[0546] Just- Val - Cit - PABC - ICQN-1 (cuttable) (VB179) Bad- Val - Cit - PABC-ICQO-1 (VB185) Wrong- PEG4 - Val - Cit - PABC - ICQN-1 (VB199) Mal- PEG4 - Val - Cit - PABC - ICQO-1( VB279 & VB288) Mal- Val - Cit - PABC - NI313 (VB277) Wrong- ICQN-1 (Irremovable) (VB284) MCC- ICQN-1 (Irremovable) (VB289)
[0547] Compounds VB179, VB185, VB199, and VB279 were obtained by activating the NH2 functional group of the compound having formula (I) (ICQN-1) according to the present invention with para-nitrophenyl chloroformate. The formed intermediate reacts with the benzyl alcohol functional group of the linker MC-Val-Cit-PABA. Compound VB277 was prepared by activating the benzyl alcohol functional group of the linker MC-Val-Cit-PABA in the trilate form, followed by a reaction with compound NI313 in a basic medium.
[0548] Compounds VB284 and VB289 were prepared by peptide coupling between ICQN-1 and an acid functional group.
[0549] VB179 :
[0550] 1 ¹H NMR(400 MHz, DMSO- d 6 ) δ: 8.58(s, 1H), 8.06(d, J = 7.3 Hz, 1H), 7.96(d, J = 7.8 Hz, 1H), 7.79(d, J = 8.4 Hz, 1H), 7.67(t, J = 7.6 Hz, 1H), 7.60(s, 1H), 7.58(s, 2H), 7.56(s, 1H), 7.49(dd, J = 8.6, 1.1 Hz, 1H), 7.34(m, 1H), 7.31(s, 1H), 6.98(s, 2H), 6.94(d, J = 8.8 Hz, 1H), 6.74(dd, J = 8.7, 2.7 Hz, 1H), 5.97(t, J= 5.8 Hz, 1H), 5.40(s, 2H), 5.00(s, 2H), 4.38(td, J = 8.2, 5.5 Hz, 1H), 4.18(dd, J = 8.3, 7.1 Hz, 1H), 3.77(s, 3H), 3.43(s, 3H), 2.97(m, 2H), 2.15(m, 2H), 1.97(dq, J = 13.5, 6.7 Hz, 1H), 1.70(m, 1H), 1.57(m, 1H), 1.52 -1.47(m, 2H), 1.45(d, J = 7.3 Hz, 2H), 1.42 -1.30(m, 2H), 1.23 -1.14(m, 2H), 0.85(d, J = 6.7 Hz, 3H), 0.82(d, J = 6.7 Hz, 3H). HRMS(ESI): m / z [M + H] C 47 H 55 N 10 O9에 대해, 계산값: 903,4153 발견값: 903,4156. 순도: 98.2%
[0551] VB 199 :
[0552] 1 H NMR(400 MHz, DMSO- d 6 ) δ: 8.58(s, 1H), 8.06(d, J = 7.3 Hz, 1H), 7.96(d, J = 7.8 Hz, 1H), 7.79(d, J = 8.4 Hz, 1H), 7.67(t, J = 7.6 Hz, 1H), 7.60(s, 1H), 7.58(s, 2H), 7.56(s, 1H), 7.49(dd, J = 8.6, 1.1 Hz, 1H), 7.34(m, 1H), 7.31(s, 1H), 6.98(s, 2H), 6.94(d, J = 8.8 Hz, 1H), 6.74(dd, J = 8.7, 2.7 Hz, 1H), 5.97(t, J= 5.8 Hz, 1H), 5.40(s, 2H), 5.00(s, 2H), 4.38(td, J = 8.2, 5.5 Hz, 1H), 4.18(dd, J = 8.3, 7.1 Hz, 1H), 3.77(s, 3H), 3,62 -3,47(m, 10 2H), 3.43(s, 3H), 2.97(m, 2H), 1.97(dq, J = 13.5, 6.7 Hz, 1H), 1.70(m, 1H), 1.57(m, 1H), 1.42 -1.30(m, 2H), 0.85(d, J = 6.7 Hz, 3H), 0.82(d, J = 6.7 Hz, 3H). HRMS(ESI): m / z [M + H] C 52 H 65 N 10 O 13 For, Calculated value: 1037.4733 Discovery value: 1037.4727. Purity: 96.0%
[0553] VB277
[0554] HRMS(ESI): m / z [M + H] C 49 H 57 N 10 For O9, calculated value: 929.4310 found value: 929.4312.
[0555] VB284
[0556] 1 H NMR (300 MHz, CDCl3) δ: 8.48(d, J = 1.9 Hz, 1H), 8.04(d, J = 9.1 Hz, 1H), 7.83(s, 1H), 7.73 -7.55(m, 2H), 7.21(s, 1H), 6.74(d, J = 8.7 Hz, 1H), 6.71(s, 2H), 6.53(d, J = 9.6 Hz, 1H), 3.90(s, 2H), 3.57(m, 2H), 3.53(s, 3H), 2.43(t, J= 7.3 Hz, 2H), 1.76(m, 4H), 1.42(m, 2H). HRMS(ESI): m / z [M + H] C 28 H 28 For N5O4, Calculated value: 498.2141 Discovery value: 498.2140. Purity: 100%
[0557] VB289
[0558] 1 H NMR (300 MHz, CDCl3) δ: 8.46(d, J = 2.3 Hz, 1H), 8.02(d, J = 8.8 Hz, 1H), 7.86(s, 1H), 7.70 -7.54(m, 2H), 7.34 -7.23(m, 1H), 7.18(s, 1H), 6.71(s, 2H), 6.45(dd, J = 8.6, 2.5 Hz, 1H), 3.87(s, 3H), 3.46(s, 3H), 3.40(d, J = 6.6 Hz, 2H), 2.30 -2.16(m, 1H), 2.10 -1.97(m, 2H), 1.87 -1.76(m, 2H), 1.54(ddd, J = 25.0, 13.1, 3.0 Hz, 2H), 1.16 -0.98(m, 2H), 0.88(m, 1H). HRMS(ESI): m / z [M + H] C 30 H 30 For N5O4, Calculated value: 524.2298 Discovery value: 524.2300. Purity: 93%
[0559] The conjugated antibody is obtained according to the protocol described in Example 9 of the international patent application PCT / EP2018 / 058168 incorporated herein by reference (particularly, paragraph 158), and, if necessary, may be adapted to the general knowledge of a person skilled in the art and a reading of the invention.
[0560] Example 15: Evaluation of the activity of the obtained conjugated antibody
[0561] The compound (ICQN-1) according to the present invention was coupled to a different linker, and subsequently, the toxic linker was conjugated to the antibody Trastuzumab to obtain a different ADC. Among the prepared ADCs, the following ADC having DAR 4, Trastuzumab-Mal-PEG4-Val-Cit-PABC-ICQN-1, was used with the gastric carcinoma cell line NCI-N87 (IC 50 It demonstrated in vitro nanomolar activity for (= 9 nM). By comparison, the reference ADC with reference payload MMAE: Trastuzumab-Mal-Val-Cit-PABC-MMAE showed nearly equivalent cytotoxic activity (IC6 nM). 50 ).
Claims
Claim 1 Compound having chemical formula (I): (I) Where: - R1 represents -NH2, -CH=CH-CO-NH-OH, -CH=CH-CH2-CH2-CO-NH-OH, -C≡C-CH2-CH2-CO-NH-OH or -OH group; - R2 represents -OCH3, -OCH2CH3 or -OCHF2 group; - R3 represents a hydrogen atom; - R4 represents a hydrogen atom; or its base or acid, or a salt of an acid or a salt of a base; or its hydrate or solvate. Claim 2 A compound according to claim 1, characterized by having the following chemical formula (Ia): (Ia) Where: - R1 represents -NH2, -CH=CH-CO-NH-OH, -CH=CH-CH2-CH2-CO-NH-OH, -C≡C-CH2-CH2-CO-NH-OH or -OH group; - R2 represents -OCH3, -OCH2CH3 or -OCHF2 group; or its base or acid, or a salt of an acid or a salt of a base; or its hydrate or solvate. Claim 3 A compound or its base or acid, or a salt of an acid or a salt of a base, characterized in that R2 represents an -OCH3 group in claim 1; or a hydrate or solvate thereof. Claim 4 In claim 1, a compound or its base or acid, or a salt of an acid or a salt of a base, characterized in that R1 represents a -NH2 or -OH group; or a hydrate or solvate thereof. Claim 5 A compound according to claim 1, characterized by being selected from the following: , , and or its base or acid, or the salt of the acid or the salt of the base; or its hydrate or solvate. Claim 6 A compound according to claim 1, characterized by having the following chemical formula (Ib): (Ib) Where: - R5 represents a hydrogen atom; - R2 represents an -OCH3, -OCH2CH3 or -OCHF2 group; - R3 represents a hydrogen atom; - R4 represents a hydrogen atom; or its base or acid, or a salt of an acid or a salt of a base; or its hydrate or solvate. Claim 7 A compound or its base or acid, or a salt of an acid or a salt of a base, characterized in that R1 represents a -CH=CH-CO-NH-OH, -CH=CH-CH2-CH2-CO-NH-OH, or -C≡C-CH2-CH2-CO-NH-OH group; or a hydrate or solvate thereof. Claim 8 A compound characterized by having the chemical formula (Ic) in claim 1: (Ic) Where: - W represents -CH=CH- or -C≡C-; - When W represents -CH=CH-, n is 0 or 2, or when W represents -C≡C-, n is 2; - R2 represents -OCH3, -OCH2CH3, or -OCHF2 groups; - R3 represents a hydrogen atom; - R4 represents a hydrogen atom; or its base or acid, or a salt of an acid or a salt of a base; or its hydrate or solvate. Claim 9 In claim 8, a compound characterized by being selected from the following: , ,and or its base or acid, or the salt of the acid or the salt of the base; or its hydrate or solvate. Claim 10 A method for preparing a compound having formula (I) according to claim 1, or a base or acid thereof, or a salt of an acid or a salt of a base thereof; or a hydrate or solvate thereof, wherein R1 represents an NH2 or -OH group, and is characterized by the following: - A compound having formula (B) is brought into contact with a compound having formula (D) to form a compound having formula (E) by an aromatic nucleophilic substitution reaction or by a coupling reaction in the presence of a catalyst; and the compound having formula (E) is methylated and subsequently reduced or deprotected to form a compound having formula (I): (B) Here, R2 is as defined in Clause 1, and R9 represents -NO2 or -O-benzoyl group; (D) Here, R3 and R4 are as defined in Article 1; (E) Here, R3, R4, and R2 are as defined in Article 1, and R 10 represents a -NO2 or -O-benzoyl group; (I) Here, R3, R4 and R2 are as defined in Article 1, and R1 represents an -NH2 or -OH group. Claim 11 A method for preparing a compound of formula (Ic) according to claim 8, or its base or acid, or a salt of an acid or a salt of a base; or a hydrate or solvate thereof, characterized in that:- A compound having formula (N) is brought into contact with a compound having formula (O) to form a compound having formula (P) by an aromatic nucleophilic substitution reaction followed by a methylation reaction: (N) Here, R3 and R4 are as defined in Clause 8, and (O) Here, R2 is as defined in Clause 8, and (P) Here, R3, R4 and R2 are as defined in Clause 8; - The compound having formula (P) undergoes an organometallic coupling reaction with -CH=CH-CO-NH-O-(2-tetrahydropyranyl), -CH=CH-CH2-CH2-CO-NH-O-(2-tetrahydropyranyl), or -C≡C-CH2-CH2-CO-NH-O-(2-tetrahydropyranyl) groups, followed by a deprotection reaction to form a compound having formula (Ic): (Ic) Here, W represents -CH=CH- or -C≡C-; when W represents -CH=CH-, n is 0 or 2, or when W represents -C≡C-, n is 2; and R3, R4 and R2 are as defined in the 8th term. Claim 12 An intermediate compound having the chemical formula (I) according to claim 1, or its base or acid, or its salt or its salt; or an intermediate compound for preparing a hydrate or solvate thereof, characterized by being selected from the following: , , , and .
